

**CURRICULUM VITAE**  
G. Caleb Alexander, MD, MS

**PERSONAL DATA**

*Business Address*

Johns Hopkins School of Public Health  
Center for Drug Safety and Effectiveness  
Department of Epidemiology  
615 N. Wolfe Street W6035  
Baltimore, MD 21205  
Phone: 410 955 8168  
Fax: 410 955 0863  
Email: galexand@jhsph.edu

*Clinical Address*

Johns Hopkins at Green Spring Station  
10753 Falls Road Suite 325  
Lutherville, MD 21093  
Clinic Phone: 410 583 2926  
Clinic Fax: 410 583 2883

**EDUCATION AND TRAINING**

1988-1990	Candidate for BA, Oberlin College
1991-1993	University of Pennsylvania, BA (Philosophy)
1994-1998	Case Western Reserve University, MD
1998-1999	Intern, Internal Medicine, University of Pennsylvania
1999-2001	Resident, Internal Medicine, University of Pennsylvania
2001-2003	Robert Wood Johnson Clinical Scholar, University of Chicago
2002-2003	University of Chicago, Department of Health Studies, MS

*Medical Licensure*

Maryland Physician and Controlled Substance License, through 6/30/24  
Drug Enforcement Agency Controlled Substance Licensure, through 6/30/24

*Medical Board Certification*

American Board of Internal Medicine, through 12/31/22

**PROFESSIONAL EXPERIENCE**

2001-2003	Off-tour Attending Physician, Veterans Affairs Hospital, Hines, Illinois
2003-2005	Instructor, Division of General Medicine, University of Chicago
2003-2006	Affiliate Faculty, Robert Wood Johnson Clinical Scholars Program
2003-2012	Affiliate Faculty, MacLean Center for Clinical Medical Ethics
2005-	Adjunct Research Associate, Department of Pharmacy Practice, University of Illinois at Chicago School of Pharmacy
2005-2011	Assistant Professor, Division of General Medicine, University of Chicago

2007-2012	Affiliate Faculty, Center for Interdisciplinary Health Disparities Research (CIHDR), University of Chicago
2011-2012	Associate Professor, Division of General Medicine, University of Chicago
2012-	Founding Co-Director, Johns Hopkins Center for Drug Safety and Effectiveness Hopkins University
2012-2018	Associate Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health
2014-	Affiliate Faculty, Center for Health Services and Outcomes Research (CHSOR), Johns
2018-	Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health

## PROFESSIONAL ACTIVITIES

### *Society Membership and Leadership*

1998-2001	Philadelphia County Medical Society
1998-2009	American Medical Association
1998-	Physicians for Social Responsibility
1998-	Alpha Omega Alpha Medical Honors Society
2000-	Society for General Internal Medicine
2000-	American College of Physicians
2003-2009	American Society of Bioethics and Humanities
2006-2007	Chair, Program Committee, RWJ Faculty Scholars National Meeting
2006	Member, Program Committee, RWJ Faculty Scholars National Meeting
2007-	International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
2008	Selection Committee, Midcareer Research Mentorship Award, SGIM
2009-	International Society for Pharmacoepidemiology (ISPE)

### *Non-Commercial Advisory Boards*

2000-2003	Transplant Task Force, End Stage Renal Disease Renal Network #9/#10
2005	American Society of Bioethics and Humanities President's Advisory Committee on Ethics Standards
2007-2011	Cost of Cancer Care Task Force, American Society of Clinical Oncology
2008-2016	Charter Member, IMS Health Services Research Network
2010-2014	FDA, Drug Safety and Risk Management Advisory Committees, Ad Hoc Member <ul style="list-style-type: none"> <li>• October 2010 Cardiovascular and Renal Committee (Darbapoeitin)</li> <li>• October 2012 Endocrinologic and Metabolic Committee (lomitapide/mipomersen)</li> <li>• July 2013 Arthritis Committee (Criteria for axial spondyloarthritis)</li> <li>• November 2013 Peripheral &amp; Central Nervous System Committee (Alemtuzumab)</li> <li>• May 2014 Public Meeting (Post Marketing Requirements for Opioid Analgesics)</li> <li>• July 2015 Bone, Reproductive and Urologic Drugs Committee (Flibanserin)</li> <li>• December 2015 Pulmonary &amp; Allergy Drugs Committee (Cough Syrup/Codeine)</li> <li>• October 2016 Bone, Reproductive and Urologic Drugs Committee (desmopressin)</li> <li>• November 2017 Psychopharmacologic Drugs Advisory Committee (buprenorphine)</li> </ul>
2014-2019	Chairman, FDA Peripheral and Central Nervous System Drugs Advisory Committee <ul style="list-style-type: none"> <li>• November 2015 Peripheral &amp; Central Nervous System Committee (Drisapersen)</li> <li>• April 2016 Peripheral &amp; Central Nervous System Committee (Eterplirsen)</li> <li>• April 2018 Peripheral &amp; Central Nervous System Committee (Cannabidiol)</li> </ul>
2020-	Member, FDA Peripheral and Central Nervous System Drugs Advisory Committee <ul style="list-style-type: none"> <li>• November 2020 Peripheral &amp; Central Nervous System Committee (Aducanumab)</li> </ul>

2015-2018 Center of Excellence for Comparative Effectiveness, University of Illinois at Chicago  
 2015-2017 Legal Science, LLC, contract through National Institutes of Drug Abuse to develop Prescription Drug Abuse Policy System  
 2016-2016 Scientific Advisory Board, Media Policy Center, Santa Monica, California  
 2016 Facilitator, Prioritizing Comparative Effectiveness Research Questions for Preventing Opioid Misuse in the Management of Pain: A Stakeholder Workshop (PCORI)  
 2020-2021 U.S. Department of Health and Human Services, National Center for Health Statistics (NCHS), National Ambulatory Medical Care Survey (NAMCS) Workgroup  
 2020 Member, FDA Peripheral and Central Nervous System Drugs Advisory Committee  
 2020 National Academies of Science, Engineering and Medicine (NASEM). Equitable Distribution of a COVID-19 Vaccine. Reviewer.  
 2020-2021 Scientific Advisory Board. Spreading the Word: Training Journalists and Researchers to Communicate PCORI Comparative Effectiveness Research Findings.  
 2021 Agency for Healthcare Research and Quality (AHRQ). Integrated Pain Management Programs: An Evidence-based Practice Center Review. Technical Expert Panelist.

*Commercial Advisory Boards*

2007-2018 IQVIA Institute for Healthcare Informatics  
 2014-2016 PainNavigator, LLC, Minneapolis, Minnesota  
 2015-2019 Delta Faucet Company, Indianapolis, Indiana  
 2016-2018 MesaRx Innovations, New York, New York  
 2017- OptumRX National P&T Committee

*Other Commercialization Activity*

2017- Co-Founder, Monument Analytics, A Health Care Consultancy

*Testimony and Briefings (Non-Litigation)*

2012 Food and Drug Administration (Drug Labeling for Prescription Opioids)  
 2015 U.S. Senate Veterans' Affairs Committee (Prescription Opioids)  
 2016 Centers for Disease Control and Prevention (Prescription Opioids)  
 2016 Committee on Health and Government Operations, Maryland House of Delegates (Prescription Drug Monitoring Programs)  
 2016 Food and Drug Administration (Prescription Opioids)  
 2016 National Academy of Sciences, Institute of Medicine (Regulation of Opioids)  
 2017 Senate Finance Committee, Maryland House of Delegates (Prescription Drug Pricing)  
 2017 U.S. House of Representatives, Congressional Oversight Committee (Opioid Epidemic)  
 2018 Briefing for U.S. Senate Staff Hosted by Senator Ben Cardin (Opioid Epidemic)  
 2018 National Academy of Science, Engineering and Medicine (FDA Opioid Regulation)  
 2019 Maryland House of Delegates (Prescription Drug Monitoring Program)  
 2019 National Academy of Science, Engineering and Medicine (Non-pharmacologic pain management)

*Other Testimony (Expert Witness for Plaintiffs in Opioid Epidemic Litigation)*

- *The County of Cuyahoga, Ohio et al. v. Purdue Pharma, L.P. and The County of Summit, Ohio et al. v. Purdue Pharma, L.P.*, U.S. District Court for the Northern District of Ohio (First bellwether trial track in In re: National Prescription Opiate Litigation)
- *State of Washington v. Purdue Pharma L.P. et al.*, Case No. 17-2-255055-0 SEA, Washington Superior Court, King County

- *State of Montana v. Purdue Pharma L.P. et al.*, Case No. 1:17-md02804, Montana First Judicial District Court, Lewis & Clark County
- *Tucson Medical Center v. Purdue Pharma L.P. et al.*, Case No. C20184213, Arizona Superior Court, Pima County
- *City of Huntington, West Virginia et al. v. AmerisourceBergen Drug Corporation et al.*, Case No. 3:17-01362, Southern District of West Virginia (Second bellwether trial track in *In re: National Prescription Opiate Litigation*)
- *People of California, acting by and through Santa Clara County et al. v. Purdue Pharma L.P. et al.*, Case No. 30-2014-00725287-CU-BT-CXC, California Superior Court, Orange County
- *State of Washington v. McKesson Corp. et al.*, Case No. 19-2-06975-9, Washington Superior Court, King County
- *County of Lake, Ohio v. Purdue Pharma, L.P., et al.*, Case No. 18-op-45032 and *County of Trumbull, Ohio v. Purdue Pharma, L.P., et al.*, Case No. 18-op-47079, Northern District of Ohio, Eastern Division (Third bellwether trial track in *In re: National Prescription Opiate Litigation*)

## EDITORIAL ACTIVITIES

### *Peer Review Activities*

#### *Ad hoc reviewer – Journals*

American Journal of Kidney Diseases	Health Services Research
American Journal of Managed Care	Hypertension
American Journal of Medicine	International Journal of Quality Improvement
American Journal of Preventive Medicine	JAMA
American Journal of Public Health	Journal of American College Health
Annals of Internal Medicine	Journal of the American Pharmacists Association
Archives of Internal Medicine	Journal of the American Society of Nephrology
BioMed Central (BMC) Gastroenterology	Journal of Clinical Ethics
BioMed Central (BMC) Infectious Diseases	Journal of General Internal Medicine
British Journal of Cancer	Journal of Rural Health
British Medical Journal	Medical Care
Canadian Medical Association Journal	Medical Decision Making
Clinical Therapeutics	Milbank Quarterly
CNS Drugs	New England Journal of Medicine
Disease Management and Health Outcomes	PharmacoEconomics
Drugs	Pharmacoepidemiology and Drug Safety
Health Affairs	Social Science and Medicine

### *Editorial Board Memberships*

2007-2010	Medical Decision Making, Deputy Editor
2008-2012	Journal of General Internal Medicine, Deputy Editor
2008-2010	Society of General Internal Medicine Forum, Associate Editor
2010-2011	BMC Health Services Research, Associate Editor
2012-2014	Journal of the American Pharmacists Association (JAPhA), Editorial Board
2012-2014	Journal of General Internal Medicine, Editorial Board
2012-	Medical Care, Deputy Editor
2013-	Drug Safety, Editorial Board
2014-	Drugs – Real World Outcomes, Editorial Board

## *Grant Reviews*

1. The Netherlands Organization for Health Research and Development (ZonMw), The Ministry of Health, Welfare, and Sport, The Hague, The Netherlands (2007)
2. The University of Chicago Program for Pharmaceutical Policy (2007-2010)
3. University of Chicago/University of Illinois at Chicago CDC Center for Health Promotion Economics (2007)
4. The University of Chicago Diabetes Research and Training Center (2008).
5. Agency for Healthcare Research and Quality, Special Emphasis Panel (R18), “Optimizing Prevention and Healthcare Management for the Complex Patient.” March 2008.
6. RFA 09-003. NIH Challenge Grants in Health and Science Research (RC21). April 2009.
7. National Institute of Aging Special Emphasis Panel (PO1). Medical Professionalism and Healthcare Grants. November 2009.
8. Agency for Healthcare Research and Quality Special Emphasis Panel (R18). Comparative Effectiveness Delivery System Demonstration Grants. July 2010.
9. Agency for Healthcare Research and Quality. Centers for Education and Research in Therapeutics (CERT) (U-19) Special Emphasis Panel. July 2011.
10. Swiss National Science Foundation. Drug Lag in Switzerland: Does it Exist and Why? June 2012.
11. Dutch Ministry of Health Grant Review. Optimizing the use of Over-the-Counter Medicines. October 2012.
12. Qatar National Research Fund Reviewer. November 2012.
13. Veterans Health Affairs Health Services Research and Development (HSR&D) Center of Innovation Review. February 2012.
14. Ad hoc reviewer. Agency for Healthcare Research and Quality. Health Care Research Training (HCRT) Study Section. January 2014 – July 2015.
15. Ad hoc reviewer. Canadian Institutes of Health Research (CIHR). Review Committee for the Drug Safety and Effectiveness Network (DSEN) and the Strategy for Patient-Oriented Research (SPOR) Catalyst Grant: Methods in Post-Market Drug Safety and Effectiveness Research. January 2015.
16. Study section member. Agency for Healthcare Research and Quality. Health Care Research Training (HCRT) Study Section. August 2015 – July 2018.
17. Chairman. Patient Centered Outcomes Research Institute. Clinical Strategies for Managing and Reducing Long-Term Opioid Use for Chronic Pain Merit Review. May 2016.
18. Chairman. Patient Centered Outcomes Research Institute. Clinical Strategies for Managing and Reducing Long-Term Opioid Use for Chronic Pain Merit Review. May 2017.

19. Chairman. Patient Centered Outcomes Research Institute. Assessment of Prevention, Diagnosis, and Treatment Options (APDTO) Program. August 2017.
20. Ad hoc reviewer. Johns Hopkins Center for Injury Research and Policy. June 2020.
21. Ad hoc reviewer. National Institute on Drug Abuse Special Emphasis Panel. Pediatric Formulations and Drug Delivery Systems and Psychoactive Surveillance. August 2020.
22. Technical Expert. Integrated Pain Management Programs and Multidisciplinary, Multi-modal Treatment Models. Agency for Healthcare Research and Quality. April 2021.
23. Ad hoc reviewer. Robert Wood Johnson Foundation. Health Data for Action (Data Access Award). May 2021.
24. Ad hoc reviewer. Decoding Disparities QuickFire Challenge. Johnson and Johnson Innovation. August 2021.
25. Chairman. American Rescue Plan Act of 2021: State Planning Grants for Qualifying Community-Based Mobile Crisis Intervention Services. Centers for Medicare and Medicaid Services. September 2021.

## HONORS AND AWARDS

### *Honors*

- |           |   |
|-----------|---|
| 1993      | Cum Laude, University of Pennsylvania   |
| 1997      | Alpha Omega Alpha, Case Western Reserve University  |
| 2003-2005 | John A. Oremus Memorial Scholar (\$40,000 Research Stipend), MacLean Center for Medical Ethics, University of Chicago |
| 2006      | Top 5% of reviewers, Medical Care (also received annually through 2011)   |
| 2007      | Top 10% of reviewers, Ann Intern Med (also received 2008, 2009, 2014)   |
| 2011      | Elected Fellow of the American College of Physicians (FACP)   |
| 2011      | Top Reviewers, Pharmacoepidemiology and Drug Safety (annually through 2014)   |

### *Awards*

- |           |  |
|-----------|--|
| 2001      | Edward W. Holmes Resident Research Award, University of Pennsylvania   |
| 2006-2009 | Robert Wood Johnson Foundation Faculty Scholar Career Development Award  |
| 2007      | Research Finalist, International Society for Pharmacoeconomics and Outcomes Research, Annual Meeting                                       |
| 2008      | Outstanding Physician Scientist Award, Central Society for Clinical Research   |
| 2008      | Career development award (\$10,000 Research Stipend), Central Society for Clinical Research  |
| 2008      | Department of Medicine Research Award (awarded to trainee for mentored research; also received by mentored trainees in 2009 and 2010)      |
| 2009      | Pritzker School of Medicine Sigma Xi Award for Impact on Science (awarded to trainee for mentored research)                                |
| 2017      | American Society of Health-System Pharmacy, Drug Therapy Research Award (awarded to trainee for mentored research and cv publication #144) |
| 2020      | Robert C. Witt Award, Best Article in Journal of Risk and Insurance (Publication #197)   |

## PUBLICATIONS

*Peer Reviewed Journal Articles (names of trainees are underlined)*

1. Szele F, **Alexander GC**, Chesselet MF. "Expression of molecules associated with neuronal plasticity in the striatum after aspiration versus thermocoagulatory lesions in the adult cortex in adult rats." *Journal of Neuroscience*. 1995;15:4429-4448. PMID: 7790918
2. **Alexander GC**, Fera B, Ellis R. "From the students: learning continuous improvement by doing it." *Joint Commission Journal on Quality Improvement*. 1996;22:198-205. PMID: 8664952
3. **Alexander GC**, Sehgal AR. Dialysis patient assessments of the quality of medical care provided by generalists, nephrologists and other specialists. *American Journal of Kidney Disease*. 1998;32:284-289. PMID: 9708614
4. **Alexander GC**, Sehgal AR. Barriers to cadaveric renal transplantation among blacks, women, and the poor. *JAMA*. 1998;280:1148-1152. PMID: 9777814  

Editorial: Milford EL. Organ transplantation--barriers, outcomes, and evolving policies. *JAMA*. 1998;280:1184-1185. PMID: 9777820
5. Lewin L, Agneberg B, **Alexander GC**. A course in end-of-life care for third year medical students. *Academic Medicine*. 2000;57:519-520. PMID: 10824792
6. **Alexander GC**, Sehgal AR. Why hemodialysis patients fail to complete the transplant process. *American Journal of Kidney Disease*. 2001;37:321-328. PMID: 11157373  

Editorial: Chertow GM, Zenios SA. Gridlock on the road to kidney transplantation. *American Journal of Kidney Disease*. 2001;37:435-437. PMID: 11157389
7. Werner RM, **Alexander GC**, Fagerlin A, Ubel PA. The "hassle factor": How physicians respond when third party payers decline reimbursement for important health care services. *Archives of Internal Medicine*. 2002;162:1134-1139. PMID: 12020183
8. **Alexander GC**, Sehgal AS. Variation in access to kidney transplantation across dialysis facilities: using process of care measures for quality improvement. *American Journal of Kidney Disease*. 2002;40:824-831. PMID: 12324919  

Editorial: Powe NR, Boulware LE. The uneven distribution of kidney transplants: getting at the root causes and improving care. *American Journal of Kidney Disease*. 2002;40:861-863. PMID: 12324926
9. **Alexander GC**, Werner RM, Fagerlin A, Ubel PA. Public support for physician deception of insurance companies. *Annals of Internal Medicine*. 2003;138:472-475. PMID: 12639080
10. **Alexander GC**, Wynia MK. Ready and willing? Physicians' sense of preparedness for bioterrorism. *Health Affairs*. September/October 2003;22:189-197. PMID: 14515895
11. **Alexander GC**, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. *JAMA*. 2003;290:953-958. PMID: 12928475

12. **Alexander GC**, Werner RM, Ubel PA. The costs of denying scarcity. *Archives of Internal Medicine*. 2004;164:593-596. PMID: 15037486
13. **Alexander GC**, Casalino LP, Tseng CW, McFadden D, Meltzer DO. Barriers to patient-physician communication about out-of-pocket costs. *Journal of General Internal Medicine*. 2004;19:856-860. PMID: PMC1492500
14. **Alexander GC**, Tseng CW. Strategies to identify and assist patients burdened by out-of-pocket prescription costs. *Cleveland Clinic Journal of Medicine*. 2004;71:433-437. PMID: 15195778
15. Werner RM, **Alexander GC**, Fagerlin A, Ubel PA. Lying to insurance companies: the desire to deceive among physicians and the public. *American Journal of Bioethics*. 2004;4:1-7. PMID: 16192208
16. Dai C, Stafford RS, **Alexander GC**. National trends in Cox-2 inhibitor use since market release: non-selective diffusion of a selectively cost-effective innovation. *Archives of Internal Medicine*. 2005;165:171-177. PMID 15668363  

Editorial: Solomon DH, Avorn J. Coxibs, science, and the public trust. *Archives of Internal Medicine*. 2005;165:158-160. PMID: 15668360
17. **Alexander GC**, Casalino LP, Metlzer DO. Physician strategies to reduce patients' out-of-pocket prescription costs. *Archives of Internal Medicine*. 2005;165:633-636. PMID: 15795338
18. Buss MK, **Alexander GC**, Switzer GE, Arnold RM. Assessing competence of residents to discuss end-of-life issues with patients. *Journal of Palliative Medicine*. 2005;8:363-371. PMID: 15890047
19. Lang P, Schwarze M, **Alexander GC**. New technologies meeting old professional boundaries: the emergence of carotid artery stenting. *Journal of the American College of Surgery*. 2005;200:854-860. PMID: 15922195
20. **Alexander GC**, Mohajir N, Meltzer DO. Consumers' perceptions about risk of and access to nonprescription medications. *J Am Pharm Assoc*. 2005;45:363-70. PMID: 15991758
21. Wang YR, **Alexander GC**, Meltzer DO. Lack of effect of guideline changes on LDL cholesterol reporting and control for diabetes visits in the U.S., 1995-2004. *Diabetes Care*. 2005;28:2942-4. PMID: 16306559
22. **Alexander GC**, Kurlander J, Wynia MK. Physicians in retainer ("concierge") practice: a national survey of physician, patient, and practice characteristics. *Journal of General Internal Medicine*. 2005;20:1079-83. PMID: PMC1490281
23. **Alexander GC**, Lantos J. The doctor-patient relationship in the post-managed care era. *American Journal of Bioethics*. 2006;6:29-32. PMID: 16423784
24. Wang YR, **Alexander GC**, Meltzer DO. Screening and use of cholesterol-lowering drug therapy for primary and secondary prevention of coronary heart disease, 1999 and 2003. *Managed Care Interface*. 2006;19:25-30. PMID: 16453992
25. Piette J, Heisler M, Horne R, **Alexander GC**. A conceptually-based approach to understanding chronically-ill patients' responses to medication cost pressures. *Social science and medicine*. 2006;62:846-857. PMID: 16095789

26. Holmes HM, Cox-Hayley DM, **Alexander GC**, Sachs GA. Reconsidering medication appropriateness for patients late in life. *Archives of Internal Medicine*. 2006;166:605-609. PMID: 16567597
27. Schwarze ML, Sayla MA, **Alexander GC**. Exploring patient preferences for infrainguinal bypass surgery. *Journal of the American College of Surgery*. 2006;202:445-452. PMID: 16500249
28. **Alexander GC**, Delisser HM, Hansen-Flaschen J, Lantos J. Shoring up professionalism: building upon disagreements between house officers and attending physicians. *Canadian Family Physician*. 2006;52:286-287. PMCID: PMC1479701
29. **Alexander GC**, Sayla MA, Holmes HM, Sachs GA. Prioritizing and stopping prescription medicines. *Canadian Medical Association Journal*. 2006;174:1083-1084. PMCID: PMC1421477
30. **Alexander GC**, Hall M, Lantos J. Rethinking professional ethics in the cost-sharing era. *American Journal of Bioethics*. 2006;6:W17-W22. PMID: 16885085
31. Federman AD, **Alexander GC**, Shrank WH. Simplifying the Medicare Prescription Drug Benefit for physicians and patients. *Mayo Clinic Proceedings*. 2006;81:1217-1221. PMID: 16970218
32. Quinn MT, **Alexander GC**, Hollingsworth D, O'Connor KG, Meltzer DO, for the Corporate Contributions for Life Consortium. Design and evaluation of a workplace intervention to promote organ donation. *Progress in Transplantation*. 2006;16:253-259. PMID: 17007162
33. Colker TR, Casalino LP, **Alexander GC**, Lantos J. Should our well-child care system be redesigned? A national survey of pediatricians. *Pediatrics*. 2006;118:1852-1857. PMID: 17079554
34. **Alexander GC**, Larkin G, Wynia MK. Preparedness for bioterror and competing public health priorities: a national survey of primary care and emergency physicians. *Academic Emergency Medicine*. 2006;13:1238-1241. PMID: 16614456
35. Wang YR, **Alexander GC**, Stafford RS. Outpatient treatment and control of hypertension in Western Europe and the United States. *Archives of Internal Medicine*. 2007;167:141-147. PMID: 17242314
36. Schwarze ML, Sayla MA, **Alexander GC**. A comparison of patient and physician beliefs about infrainguinal bypass surgery: what role should surgical optimism play? *Surgery*. 2007;141:239-244. PMID: 17263981
37. Casalino LP, **Alexander GC**, Jin L, Konetzka T. General internists' views on pay-for-performance and public reporting of quality scores: a national survey. *Health Affairs*. 2007;26:492-499. PMID: 1733967
38. Pham HH, **Alexander GC**, O'Malley AS. Physician consideration of patients' out-of-pocket costs in making common clinical decisions. *Archives of Internal Medicine*. 2007;167:663-668. PMID: 17420424
39. Torke A, **Alexander GC**, Lantos J, Siegler M. The doctor-surrogate relationship. *Archives of Internal Medicine*. 2007;167:1117-1121. PMID: 17563018
40. Kuwabara SA, Van Voorhees BW, Gollan JK, **Alexander GC**. A qualitative exploration of depression in emerging adulthood. *General hospital psychiatry*. 2007;29:317-324. PMCID: PMC2769013

41. Tseng CW, Brook RH, Keeler E, Steers WN, **Alexander GC**, Waitzfelder BE, Mangione CM. Elderly patients' preferences and experiences with providers in managing their drug costs. *Journal of the American Geriatrics Society*. 2007;55:1974-1980. PMID: 1794489
42. Phongsak SK, Wynia MK, Gadon M, **Alexander GC**. Original Communication: A Qualitative Study of Physicians' Engagement in Reducing Health Care Disparities. *Journal of the National Medical Association*. 2007;99:1315-1322. PMID: PMC2575935
43. Yin W, Basu A, Zhang J, Rabbani A, Meltzer DO, **Alexander GC**. Impact of the Medicare Part D Prescription Drug Benefit on drug utilization and out-of-pocket expenditures. *Annals of Internal Medicine*. 2008;148:169-177. PMID: 18180465  
     Editorial: Stuart B. Where are the Medicare Part D claims data? *Annals of Internal Medicine*. 2008;148:1-2. PMID: 18180463
44. **Alexander GC**, Zhang J, Basu A. Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs. *Medical Care*. 2008;46:394-402. PMID 18362819
45. **Alexander GC**, Lin S, Sayla M, Wynia MK, Writing for the Data Committee of the Commission to End Health Care Disparities. Development of a measure of physician engagement in addressing racial and ethnic health care disparities. *Health Services Research*. 2008;43(2):773-84. PMID: PMC2442375
46. Rabbani A, **Alexander GC**. Out-of-pocket and total costs of fixed dose combination antihypertensives and their components. *American Journal of Hypertension*. 2008;21(5):509-13. PMID: 18437141  
     Editorial: Arredondo A. Out-of-pocket costs to users: medicine options for hypertension. *American Journal of Hypertension*. 2008;21:492-492. PMID: 18437138
47. Torke A, Simmerling M, Siegler M, Kaya D, **Alexander GC**. Rethinking the ethical framework for surrogate decision-making: a qualitative study of physicians. *Journal of Clinical Ethics*. 2008;19:110-119. PMID: 18767471
48. Torke A, **Alexander GC**, Lantos J. Substituted judgment: the limitations of autonomy in surrogate decision-making. *Journal of General Internal Medicine*. 2008;23:1514-1517. PMID: PMC2518005
49. Zhang J, Yin W, Sun S, **Alexander GC**. Impact of the Medicare Prescription Drug Benefit on the use of generic drugs. *Journal of General Internal Medicine*. 2008;23:1673-1678. PMID: PMC2533371
50. **Alexander GC**, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment for Type 2 diabetes mellitus, 1994-2007. *Archives of Internal Medicine*. 2008;168:2088-2094. PMID: PMC2868588
51. Epstein AJ, Rathore SR, **Alexander GC**, Ketcham J. Physicians' Views on Access to Prescription Drugs under Medicare Part D. *American Journal of Managed Care*. 2008;14:SP5-SP13. PMID: 18991482
52. Peek ME, Tang H, **Alexander GC**, Chin MH. National prevalence of lifestyle counseling or referral among African Americans with diabetes. *Journal of General Internal Medicine*. 2008;23:1858-1864. PMID: PMC2585691

53. Walton SM, Schumock GT, Lee KV, **Alexander GC**, Meltzer D, Stafford RS. Prioritizing medications for policy and research initiatives examining off-label prescribing. *Pharmacotherapy*. 2008;28:1443-1452. PMID: 19025425
54. Qato DM, **Alexander GC**, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medicines and dietary supplements among older adults in the United States: findings from a population-based study. *JAMA*. 2008;300:2867-2878. PMID: PMC2702513
55. Schwarze ML, Sayla MA, **Alexander GC**. Do patients with poor outcomes regret having had infrainguinal bypass surgery? *Journal of Surgical Research*. 2009;151:6-9. PMID: 17644108
56. **Alexander GC**, Stafford RS. Does comparative effectiveness have a comparative edge? *JAMA*. 2009;301:2488-2490. PMID 19531789
57. Rabbani A, **Alexander GC**. Determinants of health care use among children: evidence from rural Bangladesh. *Journal of Biosocial Science*. 2009;41:645-660. PMID: 19531272
58. Chen DT, Wynia MK, Moloney RM, **Alexander GC**. Physician knowledge of the FDA-approved indications of commonly prescribed drugs: results of a national survey. *Pharmacoepidemiology and Drug Safety*. 2009;18:1094-100. PMID: 19697444
59. Caskey R, Lindau ST, **Alexander GC**. Knowledge and early adoption of the HPV vaccine among adolescent girls and young women: results of a national survey. *Journal of Adolescent Health*. 2009;45:453-462. PMID: 19837351
- Editorial: Rodewald LE, Orenstein WA. Vaccinating adolescents – new evidence of challenges and opportunities. *Journal of Adolescent Health*. 2009;45:427-429. PMID: 19837347
60. Rathore SR, Ketcham J, **Alexander GC**, Epstein AJ. Influence of Patient Race on Physician Prescribing Decisions: A Randomized On-line Experiment. *Journal of General Internal Medicine*. 2009;11:1183-1191. PMID: PMC2771231
61. Rabbani A, **Alexander GC**. Cost savings associated with filling a three month supply of prescription medicines. *Applied Economics and Health Policy*. 2009;7:255-264. PMID: 19905039
62. Torke AM, Siegler M, Abalos A, Moloney R, **Alexander GC**. Physicians' experience with surrogate decision making for hospitalized adults. *Journal of General Internal Medicine*. 2009;24:1023-1029. PMID: PMC2726893
63. Rabbani A, **Alexander GC**. The impact of family structure on stimulant use among children with Attention Deficit Hyperactivity Disorder. *Health Services Research*. 2009;44:2060-2078. PMID: 19732168
64. **Alexander GC**, Humensky J, Guerrero C, Park H, Loewenstein G. Physician narcissism, ego threats, and confidence in the face of uncertainty. *Journal of Applied Social Psychology*. 2010;40:947-955.
65. Dorsey R, Rabbani A, Gallagher SA, Conti R, **Alexander GC**. The impact of black box warnings on the use of atypical antipsychotic medicines. *Archives of Internal Medicine*. 2010;170:96-103. PMID 20065205

Editorial: Rochon PA, Anderson GM. Prescribing optimal drug therapy for older people: sending the right message. *Archives of Internal Medicine*. 2010;170:103-106. PMID: 20065206

66. Basu A, Yin W, **Alexander GC**. The impact of Medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. *Health Services Research*. 2010;45:133-151. (National Bureau of Economic Research [NBER] Working Paper #W14413) PMID: 20002765
67. Cohen A, Rabbani A, Shah N, **Alexander GC**. Changes in glitazone use among office-based physicians in the United States, 2003-2009. *Diabetes care*. 2010;33:823-825. PMCID: PMC2845035
68. Torke AM, Moloney R, Siegler M, Abalos A, **Alexander GC**. Physicians' views on the importance of patient preferences in surrogate decision making. *Journal of the American Geriatrics Society*. 2010;58:533-538. PMID: 20158556
69. Tseng C, Brook RH, **Alexander GC**, Hixon A, Keeler E, Mangione CM, Chen R, Jackson E, Adams Dudley R. Physicians' use of health information technology and knowledge of formularies, prescription copayments, and retail drug prices. *American Journal of Managed Care*. 2010;16:e105-e110. PMID: 2037031
70. Lale A, Moloney RM, **Alexander GC**. Academic medical centers and underserved communities: modern complexities of an enduring relationship. *Journal of the National Medical Association*. 2010;102:605-613. PMID: 20690324
71. Saunders MR, Cagney KA, Ross LF, Alexander GC. Neighborhood Poverty, Racial Composition and Renal Transplant Waitlist. *American Journal of Transplantation*. 2010;10:1912-1917. PMID: 20659097
72. Qato DM, Lindau ST, Conti RM, Schumm P, **Alexander GC**. Racial and ethnic disparities in cardiovascular medication use among older adults in the United States. *Pharmacoepidemiology and Drug Safety*. 2010;19:834-842. PMID: 20681002
73. Shah ND, Montori VM, Krumholz HM, Tu K, **Alexander GC**, Jackevicius CA. Geographic Variation in the Response to FDA Boxed Warnings for Rosiglitazone. *N Engl J Med*. 2010;22:2081-2084. PMID: 21083379
74. **Alexander GC**, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medicines, 1995-2008. *Pharmacoepidemiology and Drug Safety*. 2011;20:177-84. PMCID: PMC3069498
75. **Alexander GC**, O'Connor AB, Stafford RS. Enhancing prescription drug innovation and adoption. *Annals of Internal Medicine*. 2011;154:833-837. PMID: 21690598
76. Liu FX, **Alexander GC**, Crawford SY, Pickard AS, Hedeker D, Walton SM. Impact of Medicare Part D on Emergency Department Use, Hospitalizations, and Preference-based Health Utility. *Health Services Research*. 2011;46:1104-1123. PMID: 21609328
77. Higashi AS, Zhu S, Stafford RS, **Alexander GC**. National trends in outpatient asthma treatment, 1997-2009. *Journal of General Internal Medicine*. 2011;26:1465-70. Epub 2011 Jul 16. PMID: 21769507

78. Redmann AJ, Brasel KJ, **Alexander GC**, Schwarze ML. Use of Advanced Directives for High Risk Operations: A National Survey of Surgeons. *Annals of Surgery*. 2012;255:418-423. PMID: 22167006
79. Qato DM, **Alexander GC**. Post-Marketing Drug Safety and the Food and Drug Administration's Risk Evaluation and Mitigation Strategies. *JAMA*. 2011;306:1595-1596.
80. Brush DR, Brown CE, **Alexander GC**. Critical care physicians' approaches to negotiating with surrogate decision makers: a qualitative study. *Critical Care Medicine*. 2012;40:1080-1087. PMID: 22080645
- Editorial: Siegel MD, Perez MT. Within the black box: Exploring how intensivists resolve conflict at the end-of-life. *Critical Care Medicine*. 2012;40:1339-1340.
81. Pillarella J, Higashi A, **Alexander GC**, Conti R. Trends in the use of atypical antipsychotics for the treatment of bipolar disorder in the United States, 1998-2009. *Psychiatric services*. 2012;63:83-86.
82. Garfield CF, Dorsey ER, Zhu S, Huskamp HA, Conti R, Dusetzina SB, Higashi A, Perrin J, **Alexander GC**. U.S. Trends in the Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder, 2000-2010. *Academic Pediatrics*. 2012;12:110-116.
83. Ross JS, Jackevicius CA, Krumholz HM, Ridgeway JL, Montori VM, Alexander GC, Zerzan JT, Fan J, Shah ND. State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning. *Health Affairs*. 2012;31:188-98.
84. Dusetzina SB, Higashi A (\*co-first author), Dorsey ER, Conti R, Huskamp HA, Zhu S, Garfield CF, **Alexander GC**. Impact of FDA risk communications on health care utilization and health behaviors: a systematic review. *Medical Care*. 2012;50:466-78
- Editorial: Dal Pan GJ. Communicating the risks of medicines: time to move forward. *Medical Care*. 2012;50:463-465.
85. Pham-Kanter G, **Alexander GC**, Nair K. Effect of financial disclosure laws on physician prescribing. *Archives of Internal Medicine*. 2012;172:819-821.
86. Paczynski RP, **Alexander GC**, Chinchilli VM, Kruszewski SP. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications. *International Journal of Risk and Safety in Medicine*. 2012;24:137-146.
87. Kirley K, Qato DM, Kornfield R, Stafford RS, **Alexander GC**. National trends in oral anticoagulant use in the United States, 2007-2011. *Circulation: Cardiovascular Outcomes and Quality*. 2012;5:615-621.
88. **Alexander GC**, Lambert BL. Is Treatment Heterogeneity an Achilles' Heel for Comparative Effectiveness Research? *Pharmacotherapy*. 2012;32:583-585.
89. Brush DR, Rasinski KA, Hall JB, **Alexander GC**. Recommendations to limit life support: A national survey of critical care physicians. *American Journal of Respiratory and Critical Care Medicine*. 2012;186:633-639.
- Editorial: Hillman KM. Limitations at the End of Life. *American Journal of Respiratory and Critical Care Medicine*. 2012;186:581-582.

90. Schwarze ML, Redmann AJ, **Alexander GC**, Brasel KJ. Surgeons expect patients to buy-in to postoperative life support preoperatively: Results of a national survey. *Critical Care Medicine*. 2012;41:1-8.
- Editorial: Buchman TG. Informal Contracts, Shared Decision Making, and the Covenant of Care. 2012;41:326-327.
91. **Alexander GC**, Kruszewski SP, Webster DW. Rethinking Opioid Prescribing to Protect Patient Safety and Public Health. *JAMA*. 2012;308:1865-1866.
92. Schwarze ML, Redmann AJ, Brasel KJ, **Alexander GC**. The role of surgeon error in withdrawal of postoperative life support. *Annals of Surgery*. 2012;256:10-15.
93. Dusetzina SB, Busch AB, Conti RM, Donohue JM, **Alexander GC**, Huskamp HA. Changes in Antipsychotic Use among Patients with Severe Mental Illness after an FDA Advisory. *Pharmacoepidemiology and Drug Safety*. 2012;21:1251-1260.
94. Graziul C, Gibbons R, **Alexander GC**. Association between the commercial characteristics of psychotropic drugs and the probability of their off-label use. *Medical Care*. 2012;50:940-947.
95. deSouza JA, Polite B, Perkins M, Meropol NJ, Ratain MJ, Newcomer LN, **Alexander GC**. Unsupported off-label chemotherapy in metastatic colon cancer. *BMC Health Services Research*. 2012;12:481.
96. Kozman D, Graziul C, Gibbons R, **Alexander GC**. Association between unemployment rates and prescription drug utilization in the United States, 2007-2010. *BMC Health Services Research*. 2012;12:1-8.
97. Tan J, **Alexander GC**, Segal J. Academic Centers Play A Vital Role in the Study of Drug Safety and Effectiveness. *Clinical Therapeutics*. 2013;35:380-384.
98. Kornfield R, Donohue J, Berndt ER, **Alexander GC**. Promotion of Prescription Drugs to Consumers and Providers, 2001-2010. *PLOS One*. 2013;8:1-7.
99. Olson TJP, Brasel KJ, Redmann AJ, **Alexander GC**, Schwarze ML. Surgeon-Reported Conflict With Intensivists About Postoperative Goals of Care. *JAMA Surgery*. 2013;148:29-35.
100. Dusetzina SB, Cook BL, Busch AB, **Alexander GC**, Huskamp HA. Racial-Ethnic Differences in Incident Olanzapine Use After an FDA Advisory for Patients With Schizophrenia. *Psychiatric Services*. 2013;64:83-87.
101. Kornfield R, Watson S, Higashi AS, Conti RM, Dusetzina SB, Garfield CF, Dorsey ER, Huskamp HA, **Alexander GC**. Impact of FDA Advisories on Pharmacologic Treatment of ADHD, 2004-2008. *Psychiatric Services*. 2013;64:339-46.
102. Dusetzina SB, **Alexander GC**, Freedman RA, Huskamp HA, Keating NL. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. *Breast Cancer Research and Treatment*. 2013;137:285-296.

103. Vox F, Capron AM, Kraus MF, **Alexander GC**, Kirschner KL. Balancing Burdens and Benefits: Ethical Issues of Off-Label Prescription Pharmaceutical Use. *Physical Medicine & Rehabilitation*. 2013;5:882-889.
104. Fain K, Daubresse M, **Alexander GC**. The Food and Drug Administration Amendments Act (FDAAA) and Postmarketing Commitments. *JAMA*. 2013;310:202-204.
105. Gleason PP, **Alexander GC**, Starner CI, Ritter ST, Van Houten HK, Gunderson BW, Shah ND. Health Plan Utilization and Costs of Specialty Drugs Within 4 Chronic Conditions. *Journal of Managed Care Pharmacy*. 2013;19:542-548.
106. Daubresse M, Gleason PP, Peng Y, Shah N, Ritter ST, **Alexander GC**. Impact of a Drug Utilization Review Program on High-Risk Use of Prescription Controlled Substances. *Pharmacoepidemiology and Drug Safety*. 2013;23:419-427.
- Editorial: Coplan P. Controlling Controlled Substances Abuse and Misuse by Managed Care Payers: A New Generation of Risk Management Initiatives? *Pharmacoepidemiology and Drug Safety*. 2014;23:428-430.
107. Goldberger AD, **Alexander GC**. Digitalis Use in Contemporary Clinical Practice: Refitting the Foxglove. *JAMA Internal Medicine*. 2014;174:151-154.
108. Daubresse M, Chang H-Y, Yu Y, Viswanathan S, Shah ND, Stafford RS, Kruszewski SP, **Alexander GC**. Ambulatory Diagnosis and Treatment of Nonmalignant Pain in the United States, 2000-2010. *Medical Care*. 2013;51:870-878.
109. Chien AT, Chin MH, **Alexander GC**, Tang H, Peek ME. Physician Financial Incentives and Care for the Underserved in the United States. *American Journal of Managed Care*. 2014;20:121-129.
110. Chen LY, Strain EC, Alexandre PK, **Alexander GC**, Mojtabai R, Martins SS. Correlates of Nonmedical Use of Stimulants and Methamphetamine Use in a National Sample. *Addictive Behaviors*. 2014;39:829-836.
111. Shah RD, Rasinski KA, **Alexander GC**. The Influence of Surrogate Decision Makers on Clinical Decision Making for Critically Ill Adults. *Journal of Intensive Care Medicine*. 2013;30:278-285.
112. Turner LW, Nartey D, Stafford RS, Singh S, **Alexander GC**. Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997-2012. *Diabetes Care*. 2014;37:985-992.
113. Chang HY, Daubresse M, Kruszewski SP, **Alexander GC**. Prevalence and Treatment of Pain in EDs in the United States, 2000 to 2010. *American Journal of Emergency Medicine*. 2014;32:421-431.
114. Hampton LM, Daubresse M, Chang HY, **Alexander GC**, Budnitz DS. Emergency Department Visits by Adults for Psychiatric Medication Adverse Events. *JAMA Psychiatry*. 2014;71:1006-1014.
115. Naci H, **Alexander GC**. Regulators Should Better Leverage Effectiveness Standards to Enhance Drug Value. *Pharmacotherapy*. 2014;34:1005-1011.
116. Starner CI, **Alexander GC**, Bowen K, Qui Y, Wickersham P, Gleason PP. Specialty Drug Coupons Lower Out-of-pocket Costs and May Improve Adherence at the Risk of Increasing Premiums. *Health Affairs*. 2014;33:1761-1769.

117. Hwang C, Chang HY, **Alexander GC**. Impact of Abuse-Deterrent OxyContin on Prescription Opioid Utilization. *Pharmacoepidemiology and Drug Safety*. 2015;24:197-204.
118. Hwang C, Turner L, Kolodny A, Kruszewski SP, **Alexander GC**. Research Letter: Prescription Drug Abuse: A National Survey of Primary Care Physicians. *JAMA Internal Medicine*. 2015;175:302-304.
119. Burcu M, **Alexander GC**, Ng X, Harrington D. Construct Validity and Factor Structure of Survey-based Assessment of Cost-related Medication Burden. *Medicare Care*. 2015;53:199-206.
120. Kolodny A, Courtwright DT, Hwang CS, Kreiner P, Eadie JL, Clark TW, **Alexander GC**. The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction. *Annual Review of Public Health*. 2015;36:559-574.
121. Kornfield R, **Alexander GC**, Qato DM, Kim Y, Hirsch JD, Emery SL. Trends in Exposure to Televised Prescription Drug Advertising, 2003-2011. *American Journal of Preventive Medicine*. 2015;48:575-579.
122. Turner LW, Kruszewski SP, Mojtabai R, Webster D, Nesbit S, Stafford RS, **Alexander GC**. Trends in Buprenorphine Utilization in the United States, 1997-2012. *American Journal on Addictions*. 2015;24:24-29.
123. Daubresse M, **Alexander GC**. The Uphill Battle Facing Antiobesity Drugs. *International Journal of Obesity*. 2015;39:377-378.
124. Hampton LM, Daubresse M, Chang HY, **Alexander GC**, Budnitz DS. Emergency Department Visits by Children and Adolescents for Antipsychotic Drug Adverse Events. *JAMA Psychiatry*. 2015;72:292-294.
125. Viswanathan S, Justice AC, **Alexander GC**, Brown TT, Gandhi NR, McNicholl IR, Rimland D, Rodriguez-Barradas MC, Jacobson LP. Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy (HAART). *Journal of Acquired Immune Deficiency Syndromes*. 2015;69:493-498.
126. Riggs KR, Buttorff C, **Alexander GC**. Impact of Out-of-pocket Spending Caps on Financial Burden of Those with Group Health Insurance. *Journal of General Internal Medicine*. 2015;30:683-8.
127. Rutkow L, Turner L, Lucas E, Hwang CS, **Alexander GC**. Most Primary Care Physicians are Aware of Prescription Drug Monitoring Programs, But Many Find the Data Difficult to Access. *Health Affairs*. 2015;34:484-492.
128. Chang HY, Zhou M, Tang W, **Alexander GC**, Singh S. Risk of Gastrointestinal Bleeding Associated With Oral Anticoagulants: Population Based Retrospective Cohort Study. *British Medical Journal*. 2015;350:h1585.
- Editorial: Sarrazin MSV, Rose A. Safety of New Oral Anticoagulants. *British Medical Journal*. 2015;350:h1679.
129. Abraham NS, Singh S, **Alexander GC**, Heien H, Haas LR, Crown W, Shah ND. Comparative Risk of Gastrointestinal Bleeding with Dabigatran, Rivaroxaban and Warfarin: Population Based Cohort Study. *British Medical Journal*. 2015;350:h1857.

Editorial: Sarrazin MSV, Rose A. Safety of New Oral Anticoagulants. *British Medical Journal*. 2015;350:h1679.

130. Buttorff C, Andersen MS, Riggs KR, **Alexander GC**. Comparing Employer-Sponsored and Federal Exchange Plans: Wide Variations in Cost Sharing for Prescription Drugs. *Health Affairs*. 2015;34:467-476.
131. Dusetzina SB, Ellis S, Freedman RA, Conti RM, Winn AN, Chambers JD, **Alexander GC**, Huskamp HA, Keating NL. How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. *Journal of Oncology Practice*. 2015;11:313-318.
132. Saunders MR, Lee H, **Alexander GC**, Tak HJ, Thistlethwaite JR, Ross LF. Racial Disparities in Reaching the Renal Transplant Waitlist: Is Geography as Important as Race? *Clinical Transplantation*. 2015;29:531-538.
133. Zhou M, Daubresse M, Stafford RS, **Alexander GC**. National Trends in the Ambulatory Treatment of Hypertension in the United States, 1997-2012. *PLoS One*. 2015;10:e0119292.
134. Chen LY, Crum RM, Strain EC, **Alexander GC**, Kaufmann C, Mojtabai R. Prescriptions, Nonmedical Use, and Emergency Department Visits Involving ADHD Stimulants. *Journal of Clinical Psychiatry*. 2016;77:e297-304. doi: 10.4088/JCP.14m09291.
135. Zhou M, Chang HY, **Alexander GC**, Singh S. Adherence to a Novel Oral Anti-Coagulant Among Patients with Atrial Fibrillation. *Journal of Managed Care and Specialty Pharmacy*. 2015;21:1054-62.
136. Daubresse M, Hutfless S, Kim Y, Kornfield R, Qato DM, Huang J, Miller K, Emery SL, **Alexander GC**. Effect of Direct-to-Consumer Advertising on Asthma Medication Sales and Healthcare Use. *American Journal of Respiratory and Critical Care Medicine*. 2015;192:40-46.
137. Barnes GD, Lucas E, **Alexander GC**, Goldberger ZD. National Trends in Ambulatory Oral Anticoagulant Use. *American Journal of Medicine*. 2015;128:1300-1305.
138. Gellad WF, Flynn KE, **Alexander GC**. Evaluation of Flibanserin: Science and Advocacy at the FDA. *JAMA*. 2015;314:869-870.
139. Segal J, Oppenheim E, Garrison L, Iqbal SU, Kessler M, Kallich J, **Alexander GC**. Using Certification to Promote Uptake of Real World Evidence By Payers. *Journal of Managed Care and Specialty Pharmacy*. 2016;22:191-196.
140. Hwang CS, Turner LW, Kruszewski SP, Kolodny A, **Alexander GC**. Primary Care Physicians' Knowledge and Attitudes Regarding Prescription Opioid Abuse and Diversion. *Clinical Journal of Pain*. 2016;32:279-84.
141. Rutkow L, Chang HY, Daubresse M, Webster D, Stuart E, **Alexander GC**. Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use. *JAMA Internal Medicine*. 2015;175:1642-9.
142. Kim Y, Kornfield R, Shi Y, Vera LJ, Daubresse M, **Alexander GC**, Emery S. Effects of Televised Direct-to-Consumer Advertising for Varenicline on Prescription Dispensing in the United States, 2006-2009. *Nicotine and Tobacco Research*. 2016;18:1180-7.

143. Kaufmann CN, Spira AP, **Alexander GC**, Rutkow L, Mojtabai R. Trends in prescribing of sedative-hypnotic medications in the United States: 1993-2010. *Pharmacoepidemiology and Drug Safety*. 2016;25:637-45
144. Lyapustina T, Rutkow L, Chang HY, Daubresse M, Ramji AF, Faul M, Stuart EA, **Alexander GC**. Effect of a "Pill mill" Law on Opioid Prescribing and Utilization: The Case of Texas. *Drug and Alcohol Dependence*. 2016;159:190-7.
145. Qato DM, Wilder J, Schumm P, Gillet V, Orr A, **Alexander GC**. Use of Prescription and Over-the-counter Medications and Dietary Supplements Among Older Adults in the United States: 2005-2006 to 2010-2011. *JAMA Internal Medicine*. 2016;176:473-82.
- Editorial: Steinman, MA. Polypharmacy – Time to Get Beyond Numbers. *JAMA Internal Medicine*. 2016;176:482-483.
146. Yao X, Abraham NS, **Alexander GC**, Crown W, Montori VM, Sangaralingham LR, Gersh GJ, Shah ND, Noseworthy PA. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. *Journal of the American Heart Association*. 2016;5:29-2.
147. Bakst S, Gellad WF, **Alexander GC**. Maximizing the post-approval safety of flibanserin. *Drug Safety*. 2016;39:375-80.
148. Chang HY, Lyapustina T, Rutkow L, Daubresse M, Richey M, Faul M, Stuart EA, **Alexander GC**. Impact of prescription drug monitoring programs and pill mill laws on high-volume opioid prescribers: A comparative interrupted time series analysis. *Drug and Alcohol Dependence*. 2016;165:1-8.
149. Chingcuanco F, Segal J, Kim SK, **Alexander GC**. A Systematic Review Comparing the Safety, Efficacy and Pharmacokinetic Bioequivalence of Biosimilar TNF- $\alpha$  Inhibitors to Innovative Biologics. *Annals of Internal Medicine*. Published online 2 August 2016 doi:10.7326/M16-0428
- Editorial: Zineh I, Cristi LA. The Biosimilarity Concept: Toward an Integrated Framework for Evidence Assessment. *Annals of Internal Medicine*. Published online 2 August 2016 doi:10.7326/M16-1559
150. Efird LE, Chasler J, **Alexander GC**, McGuire M. Factors Associated with Novel Anticoagulant Use for Atrial Fibrillation Within a Large Multispecialty Practice. *American Journal of Pharmacy Benefits*. 2016;8:97-102.
151. Daubresse M, Andersen M, Riggs K, **Alexander GC**. Impact of Statin Drug Coupons on Prescription Drug Utilization and Expenditures. *Pharmacotherapy*. 25 July 2016. DOI: 10.1002/phar.1802
152. Fain KM, Castillo-Salgado C, Dore DD, Segal JB, Zullo A, **Alexander GC**. Inappropriate Fentanyl Prescribing Among Nursing Home Residents in the United States. *Journal of the American Medical Directors Association*. 2017;18:138 – 144.
153. Onasanya O, Iyer G, Lucas E, Singh S, **Alexander GC**. Association Between Exogenous Testosterone and Cardiovascular Events: An Overview of Systematic Reviews. *Lancet Diabetes and Endocrinology*. 2016 Nov;4(11):943-956.
154. Andersen MS, Buttorff C, **Alexander GC**. Impact of HIE Drug Formularies on Patients' Out-of-Pocket Costs in Health Insurance Exchanges. *American Journal of Pharmacy Benefits*. 2016;8:0.

155. Cheng C, Zandi P, Stuart E, Lin CH, Su PY, **Alexander GC**, Lan TH. Association between Lithium Use and Risk of Alzheimer's Disease. *Journal of Clinical Psychiatry*. 2017 Feb;78(2):e139-e145.
156. Fain KM, **Alexander GC**, Dore DD, Segal JB, Zullo A, Castillo-Salgado C. Frequency and Predictors of Analgesic Prescribing in U.S. Nursing Home Residents with Persistent Pain. *Journal of the American Geriatrics Society*. 2017;65:286-293.
157. **Alexander GC**, Long C, Kaestner R. Association Between Prescription Drug Insurance and Hospitalization Among Medicare Beneficiaries. *Medical Care Research and Review*. Article first published online: December 1, 2016. DOI: <https://doi.org/10.1177/1077558716681920>
158. Lin D, Lucas E, Murimi I, Jackson K, Baier M, Frattaroli S, Gielen A, Moyo P, Simoni-Wastilla L, **Alexander GC**. Physician Attitudes and Experiences with Maryland's Prescription Drug Monitoring Program (PDMP). *Addiction*. 2017;112:311-319.
159. **Alexander GC**, Iyer G, Lucas E, Lin D, Singh S. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis. *American Journal of Medicine*. 2017;130:293-305.
160. Tan J, Liu S, Segal JB, **Alexander GC**, McAdams-DeMarco M. Warfarin Use and Stroke, Bleeding, and Mortality Outcomes in Patients with ESRD and Atrial Fibrillation: A Systematic Review and Meta-analysis. *BMC Nephrology*. 2016;17:157. DOI: 10.1186/s12882-016-0368-6
161. Rutkow L, Vernick JS, **Alexander GC**. More states should regulate pain management clinics to promote public health. *Am J Public Health*. 2017;107:240-243.
162. Lin D, Lucas E, Murimi IB, Kolodny A, **Alexander GC**. Financial Conflicts of Interest and Centers for Disease Control and Prevention's 2016 Guideline for Prescribing Opioids for Chronic Pain. *JAMA Internal Medicine*. 2017;177:427-428.
- Editorial: Moynihan R, Bero L. Toward a Healthier Patient Voice: More Independence, Less Industry Funding. Published online January 17, 2017. doi:10.1001/jamainternmed.2016.9179
163. Daubresse M, Saloner B, Pollack HA, **Alexander GC**. Non-Buprenorphine Opioid Utilization Among Patients Using Buprenorphine. *Addiction*. 2017;112:1045-1053.
164. Saloner B, Daubresse M, **Alexander GC**. Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multi-State Population. *Medical Care*. 2017;55:669-676.
165. Tan J, Bae S, Segal JB, **Alexander GC**, Zhu J, Segev DL, McAdams-DeMarco M. Treatment of Atrial Fibrillation with Warfarin Among Older Adults with End Stage Renal Disease. *Journal of Nephrology*. 2017;30:831-839.
166. Layton JB, Kim Y, **Alexander GC**, Emery SL. Impact of Direct-to-Consumer Advertising on Testosterone Testing and Initiation in the United States, 2009-2014. *JAMA*. 2017;317:1159-1166.
- Editorial: Kravitz RL. Direct-of-Consumer Advertising of Androgen Replacement Therapy. *JAMA*. 2017;317:1124-1125.

167. Faul M, Hilliard RM, **Alexander GC**. Decreases in Methadone Prescribing and Overdose – United States 2007-2014 and the Associations with State Preferred List Designations. *MMWR*. 2017;66:320–323.
168. Bicket MC Long J, Pronovost PJ, **Alexander GC**, Wu CL. Opioids Commonly Unused After Surgery: A Systematic Review. *JAMA Surgery*. 2017;152:1066-1071.
169. Kaufmann CN, Spira AP, **Alexander GC**, Rutkow L, Mojtabai R. Emergency Department Visits Involving Benzodiazepines and Non-Benzodiazepine Receptor Agonists. *American Journal of Emergency Medicine*. 2017;35:1414-1419.
170. Moyo P, Griffin BA, Onukwugha E, Palumbo F, Harrington D, **Alexander GC**, Simoni-Wastila L. Impact of Prescription Drug Monitoring Programs (PDMPs) on Opioid Utilization Among Medicare Beneficiaries in 10 States. *Addiction*. 2017;112:1784-1796.
- Editorial: Davis CS. Comment on Pardo (2017) and Moyo et al. (2017): Much Still Unknown About Prescription Drug Monitoring Programs. *Addiction*. 2017;112:1797-1798.
171. Canan C, Polinski JM, **Alexander GC**, Kowal MK, Brennan TA, Shrank WH. Automated Algorithms to Identify Non-Medical Opioid Use Using Electronic Data: A Systematic Review. *Journal of the American Medical Informatics Association*. 2017;24:1204-1210.
172. Rutkow L, Smith K, Lai A, Vernick J, Davis C, **Alexander GC**. Prescription Drug Monitoring Program Design and Function: A Qualitative Analysis. *Drug and Alcohol Dependence*. 2017;180:395-400.
173. Chang HY, Richards TM, Shermock KM, Elder S, Kan H, **Alexander GC**, Gallagher JM, Knudson SM, Weiner JP, Kharrazi H. Evaluating the Impact of Prescription Fill Rates on Risk Stratification Model Performance. *Medical Care*. 2017;55:1052-1060.
174. Qato DM, Zenk SN, Wilder J, Harrington R, Gaskin D, **Alexander GC**. Availability of Pharmacies and Pharmacy Services in the United States: 2007-2015. *PLoS One*. 2017;12:e0183172.
175. Seamans MJ, Carey TS, Westreich DJ, Cole SR, Wheeler SB, **Alexander GC**, Brookhart MA. Prescription Opioid Initiation Among Members of Households with a Prescription Opioid User. *JAMA Internal Medicine*. 2018;178:102-109.
176. Sharfstein JM, Miller JD, Davis AL, Ross JS, McCarthy ME, Smith B, Chaudhry A, **Alexander GC**, Kesselheim AS. Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products. *The Journal of Law, Medicine & Ethics*. 2017;45S2:7-23.
- Editorial: Davis AL, Miller JD, Sharfstein JM, Kesselheim AS. Introduction. *The Journal of Law, Medicine & Ethics*. 2017;45S1:5-6.
177. Law E, Harrington R, **Alexander GC**, Saha S, Oehrlein E, Perfetto E. Increasing the Uptake of Comparative Effectiveness and Patient-Centered Outcomes Research: A Stakeholder Conference. *Journal of Comparative Effectiveness Research*. 2018;7:181-191.

178. Shin JI, Luo S, **Alexander GC**, Inker LA, Coresh J, Chang AR, Grams ME. Direct oral anticoagulants and risk of acute kidney injury in patients with atrial fibrillation. *Journal of the American College of Cardiology*. 2018;71:251-252.
179. Chang HY, Murimi IB, Jones CM, **Alexander GC**. Relationship Between High-Risk Patients Receiving Prescription Opioids and High-Volume Opioid Prescribers. *Addiction*. 2018;113:677-686.
180. Chang HY, Murimi I, Faul M, Rutkow L, **Alexander GC**. Impact of prescription drug monitoring programs and pill mill laws on high-risk patients: A comparative interrupted time series analysis. *Pharmacoepidemiology and Drug Safety*. 2016;165:1-8.
181. **Alexander GC**, Ballreich J, Socal MP, Karmarkar T, Trujillo A, Green J, Sharfstein J, Anderson G. Reducing Prescription Drug Spending: A Review of Policy Options. *Pharmacotherapy*. 2017;37:1469-1478.
182. Ogasawara K, Breder CD, Lin DH, **Alexander GC**. Exposure- and Dose-Response Analyses in Dose Selection and Labeling of FDA Approved Biologics. *Clinical Therapeutics*. 2018;40:95-102.
183. McGinty B, Stuart EA, **Alexander GC**, Barry CL, Bicket MC, Rutkow L. Protocol: Mixed-methods study to evaluate implementation, enforcement, and outcomes of U.S. state laws intended to curb high-risk opioid prescribing. *Implementation Science*. 2018;13:37.
184. Ballreich J, **Alexander GC**, Socal MP, Karmarkar T, Anderson G. Branded Prescription Drug Spending: A Framework to Evaluate Policy Options. *Journal of Pharmaceutical Policy and Practice*. 2017;10:31.
185. Tan J, Bae S, Segal JB, Zhu J, **Alexander GC**, Segev DL, McAdams-DeMarco M. Warfarin Use and Risk of Stroke, Bleeding, And Mortality in Older Adults On Dialysis with Incident Atrial Fibrillation. *Nephrology*. *Nephrology*. 2019;24:234-244.
186. Roter DL, Narayanan S, Smith K, Bullman R, Rausch P, Wolff J, **Alexander GC**. The Role of Family Caregivers in Facilitating Safe and Effective Prescription Drug Use. *Patient Education and Counselling*. 2018;101:908-916.
187. Baksh S, DeMarco-McAdams M, Segal JB, **Alexander GC**. Cardiovascular Safety Signals with Dipeptidyl peptidase-4 (DPP-4) Inhibitors. *Pharmacoepidemiology and Drug Safety*. 2018;27:660-667.
188. Bicket MC, White E, Pronovost PJ, Wu CL, Yaster M, **Alexander GC**. Prescription Opioid Oversupply After Joint and Spine Surgery: A Prospective Cohort Study. *Anesthesia and Analgesia*. 2018 Apr 17. doi:10.1213/ANE.0000000000003364. [Epub ahead of print]
189. Jiao S, Murimi I, Stafford RS, Mojtabai R, Alexander GC. Quality of Pharmacologic Care by Physicians, Nurse Practitioners and Physician Assistants in the United States. *Pharmacotherapy*. 2018;38:417-427.
190. Tieu C, DePaola M, Lucas E, Rosman L, **Alexander GC**. Efficacy and Safety of Biosimilar Insulins Compared to Their Reference Products: A Systematic Review. *PLoS One*. April 18, 2018 <https://doi.org/10.1371/journal.pone.0195012> [Epub ahead of print]

191. Mayo-Wilson E, Heyward J, Keyes A, Reynolds J, Omar A, White S, **Alexander GC**, Ford D, on behalf of the National Clinical Trials Registration and Results Reporting Taskforce Survey Subcommittee. Clinical Trial Registration and Reporting: A Survey of Academic Organizations in the United States. *BMC Medicine*. 2018;16:60. doi: 10.1186/s12916-018-1042-6.
192. Qato DM, **Alexander GC**, Guadamuz JS, Lindau ST. Use of Dietary Supplements Among Children and Adolescents in the United States. *JAMA Pediatrics*. *JAMA Pediatr*. Published online June 18, 2018. doi:10.1001/jamapediatrics.2018.1008
193. Canan C, Chander G, Monroe A, Gebo K, Moore R, Agwu A, **Alexander GC**, Lau B. High Risk Opioid Use Among Persons Living with HIV. *Journal of Acquired Immune Deficiency Syndromes (JAIDS)*. 2018;78:1.
194. Lazarus B, Wu A, Shin JI, Sang Y, **Alexander GC**, Secora A, Inker L, Coresh J, Chang AR, Grams ME. Metformin Use and Risk of Acidosis Across the Range of Kidney Function: A Community-based Cohort Study. *JAMA Internal Medicine*. Publication pending. doi:10.1001/jamainternmed.2018.0292
- Editorial: Good CB, Pogach LM. Should Metformin Be First-Line Therapy for Patients with Type 2 Diabetes and Chronic Kidney Disease? *JAMA Internal Medicine*. Published online June 4, 2018. doi:10.1001/jamainternmed.2018.0301
195. Lin DH, Jones CM, Compton WM, Heyward J, Losby JL, Murimi IB, Baldwin GT, Ballreich JM, Thomas D, Bicket M, Porter L, Tierce JC, **Alexander GC**. Prescription Drug Coverage for Low Back Pain Among U.S. Medicaid, Medicare Advantage and Commercial Insurers. *JAMA Network Open*. 2018;1:e180235. doi:10.1001/jamanetworkopen.2018.0235
- Editorial: Waljee JF, Brummett CM. Opioid Prescribing for Low Back Pain: What is the Role of Payers? *JAMA Network Open*. 2018;1:e180236. doi:10.1001/jamanetworkopen.2018.0236
196. Saloner B, Stoller K, **Alexander GC**. Buprenorphine and Medication Assisted Treatment: Crossing the Quality Chasm. *N Engl J Med*. 2018;379:4-6.
197. Kaestner R, Schiman C, Alexander GC. Effects of Prescription Drug Insurance on Hospitalization and Mortality: Evidence from Medicare Part D. *Journal Risk and Insurance*. 2019;86:595-628. (National Bureau of Economic Research (NBER) Working Paper #W19948.)
198. Lai AY, Smith KC, Vernick JS, Davis CS, **Alexander GC**, Rutkow L. Perceived Unintended Consequences of Prescription Drug Monitoring Programs: A Qualitative Assessment. *Substance Use and Misuse*. 2019;54:345-349.
199. Chang HY, Singh S, Mansour O, Baksh S, **Alexander GC**. Association Between Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitors and Lower Extremity Amputation: A Retrospective Cohort Study. *JAMA Internal Medicine*. Published online August 13, 2018. doi:10.1001/jamainternmed.2018.3034
- Editorial: Fralick M, Paterno E, Fischer MA. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Amputation: Results and Challenges from the Real World. Published online August 13, 2018. doi:10.1001/jamainternmed.2018.3025
200. Sibia US, Mandelblatt AE, **Alexander GC**, King PJ, MacDonald J. Opioid Prescriptions after Total Joint Arthroplasty. *Journal of Surgical Orthopaedic Advances*. 2018;27:231-236.

201. Shin JI, Secora A, **Alexander GC**, Inker LA, Coresh J, Chang AR, Grams ME. Risks and Benefits of Direct Oral Anticoagulants Across the Spectrum of Glomerular Filtration Rate Among Patients with Atrial Fibrillation. *Clinical Journal of the American Society of Nephrology*. 2018;13:1144-1152.
202. Zhu J, **Alexander GC**, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017. *Pharmacotherapy*. 2018;38:907920.
203. Chang HY, Kharrazi H, Bodycombe D, Weiner J, **Alexander GC**. Healthcare Costs and Utilization Associated with High Risk Prescription Opioid Use. *BMC Medicine*. 2018;16:69.
204. Secora A, **Alexander GC**, Coresh H, Grams M. Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-based Cohort of Older Adults. *Drugs and Aging*. 2018;35:735-750.
205. Saloner B, Levin J, Chang HY, Jones C, **Alexander GC**. Buprenorphine and Opioid Pain Relieve Use After the ACA Medicaid Expansion. *JAMA Network Open*. 2018;1:e181588. doi:10.1001/jamanetworkopen.2018.1588.
206. **Alexander GC**, Ogasawara K, Wiegand D, Lin D, Breder CD. Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016. *Therapeutic Innovation & Regulatory Science*. 2018 Dec 3:2168479018812058. doi: 10.1177/2168479018812058. [Epub ahead of print]
207. Qato DM, **Alexander GC**, Guadamuz J, Lindau ST. Prescription Medication Use Among Children and Adolescents in the United States. *Pediatrics*. 2018;142:e20181042.
208. Heyward J, Padula W, Tierce J, **Alexander GC**. The Value of U.S. Pharmacopeial Standards: A Review of the Literature. *Pharmaceutical Sciences*. 2018 June 13. <https://doi.org/10.1016/j.xphs.2018.06.004> [epub ahead of print]
209. Moore TJ, Zhang H, Anderson G, **Alexander GC**. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. *JAMA Internal Medicine*. 2018 September 24. doi:10.1001/jamainternmed.2018.3931 [epub ahead of print]
- Editorial Comment: Ross JS. Clinical Trials – We Get What We Pay For. *JAMA Intern Med*. 2018 September 24. doi:10.1001/jamainternmed.2018.3930 [epub ahead of print]
210. Heyward J, Jones CM, Compton WM, Lin DH, Losby JL, Murimi IB, Baldwin GT, Ballreich JM, Thomas D, Bicket M, Porter L, Tierce JC, **Alexander GC**. Coverage of Non-Pharmacologic Treatments for Lower Back Pain Among Public and Private Insurers in the United States. *JAMA Network Open*. 2018;1(6):e183044. doi:10.1001/jamanetworkopen.2018.3044 [epub ahead of print]
- Editorial Comment: Goertz CM, George SZ. Insurer Coverage for Nonpharmacologic Treatments for Low Back Pain. *JAMA Network Open*. 2018;1(6):e183037. doi:10.1001/jamanetworkopen.2018.3037 [epub ahead of print]
211. Novick TK, Surapaneni A, Shin JI, Ballew SH, **Alexander GC**, Inker LA, Change AR, Grams ME. Prevalence of Opioid, Gabapentin/Pregabalin, and NSAID Use in CKD. *Clin J Am Soc Nephrol*. Published on November 8, 2018. doi: 10.2215/CJN.08530718

212. Daubresse M, **Alexander GC**, Crews DC, Segev DL, McAdams-DeMarco MA. Trends in Opioid Prescribing Among Hemodialysis Patients, 2007–2014. *Am J Nephrol*. 2019;49:20-31. doi:10.1159/000495353
213. Murimi IB, Chang HY, Jones CM, Bicket M, **Alexander GC**. Using Trajectory Models to Assess the Effect of Hydrocodone Upscheduling Among Chronic Hydrocodone Users. *Pharmacoepidemiology and Drug Safety*. 2018 Sep 5. doi:10.1002/pds.4639. [Epub ahead of print]
214. Rollman JE, Heyward J, Olson L, Lurie P, Sharfstein J, **Alexander GC**. U.S. Food and Drug Administration Regulation of Transmucosal Immediate Release Fentanyls (TIRFs): A Narrative Review. *JAMA*. 2019;321:676-685. doi:10.1001/jama.2019.0235
- Editorial Comment: Sarpatwari A, Curfman G. Mitigating Health Risks of Prescription Drugs: Lessons From FDA Oversight of Opioid Products. *JAMA*. 2019;321:651-653. doi:10.1001/jama.2019.0236 [epub ahead of print]
215. Ogasawara K, **Alexander GC**. Use of Population Pharmacokinetic Analyses Among FDA-Approved Biologics. *Clinical Pharmacology in Drug Development*. 2019 Feb 1. doi: 10.1002/cpdd.658. [Epub ahead of print]
216. Heins SE, Frey KP, **Alexander GC**, Castillo RC. Reducing High-Dose Opioid Prescribing: State-Level Morphine Equivalent Daily Dose Policies, 2007-2017. *Pain Medicine*. 2019;0:1-9. doi: 10.1093/pm/pnz038
217. Canan C, **Alexander GC**, Moore R, Murimi I, Chander G, Lau B. Medicaid Trends in Opioid and Non-opioid Use by HIV Status. *Drug and Alcohol Dependence*. 2019;197:141-148.
218. Qiao Y, **Alexander GC**, Moore TJ. Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015-2016. *Clinical Trials*. First Published March 29, 2019. <https://doi.org/10.1177/1740774519839391>
219. Pilla SJ, Segal JB, **Alexander GC**, Boyd CM, Maruthur NM. Differences in National Diabetes Treatment Patterns and Trends Between Older and Younger Adults. *J Am Geriatr Soc*. 2019 Jan 31. doi: 10.1111/jgs.15790. [Epub ahead of print]
220. Xu Y, Pilla SJ, **Alexander GC**, Murimi IB. Use of Non-Insulin Diabetes Medicines After Insulin Initiation: A Retrospective Cohort Study. *PLoS One*. 2019 Feb 13;14(2):e0211820. doi: 10.1371/journal.pone.0211820. eCollection 2019.
221. Qato DM, **Alexander GC**, Chakraporty A, Guadamuz J, Jackson JW. Association Between Pharmacy Closures and Adherence to Cardiovascular Medications Among Older U.S. Adults. *JAMA Open*. 2019;2:e192606. doi:10.1001/jamanetworkopen.2019.2606
222. Trujillo AJ, Karmarkar T, **Alexander GC**, Padula W, Greene J, Anderson G. Fairness in Drug Prices: Do Economists Think Differently from the Public? *Health Econ Policy Law*. 2018 Dec 4:1-12. doi: 10.1017/S1744133118000427. [Epub ahead of print]
223. Bicket MC, Murimi I, Mansour O, Wu CL, **Alexander GC**. Association of New Opioid Continuation with Surgical Specialty and Type in the United States. *American Journal of Surgery*. <https://doi.org/10.1016/j.amjsurg.2019.04.010> [Epub ahead of print]

224. Moyo P, Griffin BA, Onukwugha E, Palumbo F, Harrington D, **Alexander GC**, Simoni-Wastila L. Prescription Drug Monitoring Programs: Assessing the Association Between “Best Practices” and Opioid Use by Disabled and Older Adults. *Health Services Research*. <https://doi.org/10.1111/1475-6773.13197> [Epub ahead of print]
225. Guadamuz J, **Alexander GC**, Uddin T, Trotsky-Sirr R, Qato DM. Availability of Naloxone Spray in Philadelphia Pharmacies, 2017. *JAMA Netw Open*. 2019 Jun 5;2(6):e195388. doi: 10.1001/jamanetworkopen.2019.5388.
226. Mojtabai R, Riehm KE, Cohen JE, **Alexander GC**, Rutkow L. Clean indoor air laws, cigarette excise taxes, and smoking: United States, 2003-2011. *Prev Med*. 2019 Jun 4;126:105744. doi: 10.1016/j.ypmed.2019.06.002. [Epub ahead of print]
227. Bicket MC, Brat G, Hutfless S, Wu C, Nesbit S, **Alexander GC**. Optimizing Opioid Prescribing and Pain Treatment for Surgery: A Conceptual Framework. *American Journal of Health-System Pharmacy*. 2019;76:1403-1412.
228. Chang HY, Daubresse M, Saloner B, **Alexander GC**. Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder. *Medical Care*. 2019;57:667-672.
229. Murimi IB, Ballreich JM, Seamans MJ, **Alexander GC**. Impact of U.S. Pharmacopeia Monograph Standards on Generic Market Entry and Prescription Drug Costs. *PLoS One*. 2019 Nov 12;14(11):e0225109. doi: 10.1371/journal.pone.0225109. eCollection 2019.
230. Qiao Y, Shin JI, Sang Y, Inker LA, Secora A, Coresh J, **Alexander GC**, Jackson J, Chang AR, Grams ME. Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. *Mayo Clinic Proceedings*. 2019 Nov;94(11):2220-2229. doi: 10.1016/j.mayocp.2019.05.031. Epub 2019 Oct 13.
231. Novick TK, Surapeneni A, Shin JI, **Alexander GC**, Inker LA, Wright EA, Chang AR, Grams ME. Associations of Opioid Prescriptions with Death and Hospitalization Across the Spectrum of Estimated GFR. *Clinical Journal of the American Society of Nephrology*. 2019 Nov 7;14(11):1581-1589. doi: 10.2215/CJN.00440119. Epub 2019 Oct 3.
232. Guadamuz J, **Alexander GC**, Zenk SN, Qato DM. Assessment of Pharmacy Closures in the United States, 2009-2015. *JAMA Internal Medicine*. Published online October 21, 2019. doi:<https://doi.org/10.1001/jamainternmed.2019.4588>
233. Li X, Anderson KM, Chang HY, Curtis J, **Alexander GC**. Comparative Risk of Serious Infection Among Real-world Users of Biologics for Psoriasis and Psoriatic Arthritis. *Annals of the Rheumatic Diseases*. 2019 Oct 31. pii: annrhumdis-2019-216102. doi: 10.1136/annrhumdis-2019-216102. [Epub ahead of print]
234. Vermeulen LC, Swarthout MD, **Alexander GC**, Ginsburg DB, Pritchett KO, White SJ, Tryon J, Emmerich C, Nesbit TW, Greene W, Fox ER, Conti RM, Scott BE, Sheehy F, Melby ME, Lantzy MA, Hoffman JM, Knoer S, Zellmer WA. ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. *American Journal of Health-System Pharmacy*. 2020;77:84–112.

235. Heyward J, Olson L, Sharfstein J, Stuart EA, Lurie P, **Alexander GC**. Oversight of Extended Release/Long Acting (ER/LA) Opioid Prescribing by the U.S. Food and Drug Administration: A Narrative Review. *JAMA Intern Med*. Published online December 30, 2019. doi:<https://doi.org/10.1001/jamainternmed.2019.5459>
- Editorial: Hubbard WK. Getting Serious About Opioid Regulation. *JAMA Intern Med*. Published online December 30, 2019. doi:<https://doi.org/10.1001/jamainternmed.2019.5443> [epub ahead of print]
236. Hsieu EHC, Moore TJ, **Alexander GC**. Costs of Pivotal Trials for FDA-Approved Cancer Drugs, 2015-2017. *Clinical Trials*. Published online February 29, 2020. <https://doi.org/10.1177/1740774520907609>
- Editorial: Bach PB. Commentary on Hsiue et al: Cost savings and data limitations of new cancer drug studies. *Clin Trials*. 2020;17(2):126-128. doi:10.1177/1740774520907668
237. Qiao Y, Shin JI, Chen T, Inker LA, Coresh J, **Alexander GC**, Jackson JW, Chang AR, Grams ME. Association between Renin-angiotensin System Blockade Discontinuation and All-cause Mortality Among People with Low Estimated Glomerular Filtration Rate. *JAMA Internal Medicine*. Published online March 9, 2020. doi:10.1001/jamainternmed.2020.0193
- Editorial: DeJong C, Grant RW. Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Face of Kidney Disease Progression—Safe and Possibly Life Saving. *JAMA Intern Med*. Published online March 9, 2020. doi:10.1001/jamainternmed.2020.0300
238. Rao T, Kiptanui Z, Dowell P, Triebwasser C, **Alexander GC**, Harris I. Formulary Restrictions for Opioid Alternatives Increase Opioid Prescribing Among Medicare Beneficiaries. *JAMA Network Open*. 2020;3:e200274. doi: 10.1001/jamanetworkopen.2020.0274.
239. **Alexander GC**, Stoller KB, Haffajee RL, Saloner B. An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. *Ann Intern Med*. 2020; [Epub ahead of print 2 April 2020]. doi: <https://doi.org/10.7326/M20-1141>
240. Mojtabai R, Riehm KE, Cohen JE, **Alexander GC**, Vernick JS, Thrul J. Cigarette Excise Taxes, Clean Indoor Air Laws, and Use of Smoking Cessation Treatments: A Mediation Analysis. *Preventative Medicine*. 2020;136: <https://doi.org/10.1016/j.ypmed.2020.106098>
241. Secora AM, Shin JI, Qiao Y, **Alexander GC**, Chang AR, Inker LA, Coresh J, Grams ME. Hyperkalemia and acute kidney injury with spironolactone use among patients with heart failure. *Mayo Clinic Proceedings*. 2020;95: <https://doi.org/10.1016/j.mayocp.2020.03.035>
242. Guadamuz J, Qato DM, **Alexander GC**. Use of Risk Evaluation and Mitigation Strategies (REMS) by the U.S. Food and Drug Administration (FDA), 2008-2019. *JAMA*. Publication pending.
243. **Alexander GC**, Qato DM. Ensuring Access to Medicines in the U.S. During the COVID-19 Pandemic. *JAMA*. Published online April 09, 2020. doi:10.1001/jama.2020.6016
244. Murimi IB, Lin DH, Nab H, Kan H, Onasanya O, Tierce JC, Wang X, Desta B, **Alexander GC**, Hammond ER. The association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis. *BMJ Open* 2020;10:e031850. doi: 10.1136/bmjopen-2019-031850

245. Stone EM, Rutkow L, Bicket M, Barry CL, **Alexander GC**, McGinty EE. Implementation and Enforcement of State Opioid Prescribing Laws. *Drug and Alcohol Dependence*. 2020;213:108107. <https://doi.org/10.1016/j.drugalcdep.2020.108107>
246. Moore TJ, Heyward J, Anderson G, **Alexander GC**. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study. *BMJ Open* 2020;10:e038863. doi: 10.1136/bmjopen-2020-038863
247. Heyward J, Mansour O, Olson L, Singh S, **Alexander GC**. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. *PLoS One*. 2020;15(6):e0234065. Published 2020 Jun 5. doi:10.1371/journal.pone.0234065
248. Mehta HB, Ehrhardt S, Moore TJ, Segal JB, **Alexander GC**. Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. *BMJ Open*. 2020;10:e039978. Published 2020 Jun 9. doi:10.1136/bmjopen-2020-039978
249. Qato DM, **Alexander GC**, Guadamuz J, Choi S, Trotzky-Sirr R, Lindau ST. Access to Pharmacist-Prescribed and Emergency Contraception in Los Angeles County, 2017. *Health Affairs*. 2020;39: <https://doi.org/10.1377/hlthaff.2019.01686>.
250. Chang HY, Kong JH, Shermock KM, **Alexander GC**, Weiner JP, Kharrazi H. Chang HY, Kong JH, Shermock KM, Alexander GC, Weiner JP, Kharrazi H. Integrating e-prescribing and pharmacy-claim data for predictive modeling: Comparing costs and utilization of health plan members who initially fill their medication orders with those who do not. *Journal of Managed Care & Specialty Pharmacy*. *J Manag Care Spec Pharm*. 2020;26;1282-1290.
251. Hussaini S, **Alexander GC**. The United States Postal Service: An Essential Public Health Agency. *Journal of General Internal Medicine*. DOI: 10.1007/s11606-020-06275-2
252. Mehta HB, Moore TJ, Alexander GC. Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin. *Psychiatr Serv*. 2020 Aug 25:appips202000251. doi: 10.1176/appi.ps.202000251. Epub ahead of print. PMID: 32838675.
253. Heyward J, Moore TJ, Chen J, Meek K, Lurie P, **Alexander GC**. Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997-2018. *Ann Intern Med*. 2020 Dec 15;173(12):956-963. doi: 10.7326/M20-0274. Epub 2020 Sep 29. PMID: 32986486.
254. Alexander GC, Tajanlangit M, Heyward J, Mansour O, Qato DM, Stafford RS. Use and content of primary care telemedicine during the COVID-19 pandemic in the United States. *JAMA Network Open*. 2020;3(10):e2021476. doi:10.1001/jamanetworkopen.2020.21476
- Editorial: Thronson LR, Jackson SL, Chew LD. The Pandemic of Health Care Inequity. *JAMA Netw Open*. 2020;3(10):e2021767. doi:10.1001/jamanetworkopen.2020.21767
255. Moore TJ, Mouslim MC, Blunt JL, **Alexander GC**, Shermock K. Assessment of Availability, Clinical Testing, and the US Food and Drug Administration Review of Biosimilar Biologic Products. *JAMA Internal Medicine*. 2020. doi: 10.1001/jamainternmed.2020.3997. Epub ahead of print. PMID: 33031559.

256. Baksh S, Segal JB, McAdams-DeMarco M, Kalyani RR, **Alexander GC**, Ehrhardt S. Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Events in Patients with Type 2 Diabetes, Without Cardiovascular or Renal Disease: A Retrospective Cohort Study: A Retrospective Cohort Study. *PLoS ONE* 15:e0240141. <https://doi.org/10.1371/journal.pone.0240141>
257. Murimi IB, Lin DH, Kan H, Tierce J, Wang X, Nab H, Desta B, **Alexander GC**, Hammond ER. Health Care Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States. *Journal of Rheumatology*. 2020. DOI: 10.3899/jrheum.191187. PMID: 32611669.
258. Ballreich J, Mansour O, Hu E, Chingcuanco F, Pollack HA, Dowdy DW, **Alexander GC**. APOLLO: A Model of the Opioid Epidemic in the United States. *JAMA Network Open*. 2020;3:e2023677. doi:10.1001/jamanetworkopen.2020.23677
259. Secora A, Shin JJ, Qiao Y, **Alexander GC**, Coresh J, Grams ME. Spironolactone Use Among Patients with Heart Failure Across the Spectrum of Kidney Function. *Mayo Clinic Proceedings*. 2020;95:DOI: <https://doi.org/10.1016/j.mayocp.2020.03.035>
260. Mouslim MC, Trujillo AJ, **Alexander GC**, Segal JB. Association Between Filgrastim Biosimilar Availability and Changes in Claims Payments and Out-of-pocket Costs for Biologic Filgrastim. *Value in Health*. 2020;<https://doi.org/10.1016/j.jval.2020.06.014>
261. Canan C, Chandler G, Moore R, **Alexander GC**, Lau B. Estimating the Prevalence of Prescription Opioid Diversion. *Drug and Alcohol Dependence*. 2020;<https://doi.org/10.1016/j.drugalcdep.2020.108398>
262. Mansour O, Tajanlangit M, Heyward J, Mojtabai R, **Alexander GC**. Office-based and Telemedicine Care for Behavioral and Psychiatric Conditions During the COVID-19 Pandemic in the United States. *Annals of Internal Medicine*. 2020 Nov 17. doi: 10.7326/M20-6243. Epub ahead of print. PMID: 33197214.
263. Foti K, Appel LJ, Matsushita K, Coresh J, **Alexander GC**, Selvin E. Digit Preference in Office Blood Pressure Measurements, United States 2014–2018. *American Journal of Hypertension*. 2020 Nov 27;hpaa196. doi: 10.1093/ajh/hpaa196. Epub ahead of print. PMID: 33246327.
264. Karmarkar T, Trujillo AJ, Padula W, Greene J, **Alexander GC**, Anderson G. Examining Fairness in the Trade-Off Between Drug Price Regulation & Investments in Research and Development. *Health Policy. Journal of Behavioral Economics for Policy*. 2020;4:49-55.
265. Park JN, Rashidi E, Foti K, Zoorob M, Sherman S, **Alexander GC**. Fentanyl and fentanyl analogs in the illicit stimulant supply: Results from U.S. drug seizure data, 2011-2016. *Drug Alcohol Depend*. 2021 Jan 1;218:108416. doi: 10.1016/j.drugalcdep.2020.108416. Epub 2020 Nov 23. PMID: 33278761; PMCID: PMC7751390.
266. Jones CM, Bekheet F, Park JN, **Alexander GC**. The Evolving Overdose Epidemic: Synthetic Opioids and Rising Stimulant-Related Harms. *Epidemiol Rev*. 2020 Jan 31;42(1):154-166. doi: 10.1093/epirev/mxaa011. PMID: 33511987.
267. Stevenson JM, **Alexander GC**, Palamuttam N, Mehta HB. Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States. *Clin Transl Sci*. 2020 Oct 21. doi: 10.1111/cts.12919. Epub ahead of print. PMID: 33085221.

268. Wang L, Paller CJ, Hong H, De Felice A, Alexander GC, Brawley O. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. *JAMA Oncol*. 2021 Jan 14:e206973. doi: 10.1001/jamaoncol.2020.6973. Epub ahead of print. PMID: 33443584; PMCID: PMC7809610.
269. Andersen K, Mehta HB, Palamuttam N, Ford D, Garibaldi BT, Auwater PG, Segal J, **Alexander GC**. Association Between Chronic Use of Immunosuppressive Drugs and Clinical Outcomes from COVID-19 Hospitalization: A Retrospective Cohort Study in a Large U.S. Health System. *Clinical Infectious Diseases*. ciaa1488, <https://doi.org/10.1093/cid/ciaa1488>
270. Guadamuz JS, McCormick CD, Choi S, Urick B, **Alexander GC**, Qato DM. Telepharmacy and medication adherence in urban areas. *J Am Pharm Assoc*. 2020:S1544-3191(20)30542-2. doi: 10.1016/j.japh.2020.10.017. Epub ahead of print. PMID: 33246835.
271. Nguyen TD, Gupta S, Ziedan E, et al. Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic. *JAMA Intern Med*. Published online December 21, 2020. doi:10.1001/jamainternmed.2020.7497
272. Lamont EB, Diamond SS, Katriel RG, Ensign L, Liu J, Rusli E, **Alexander GC**. Trends in Oncology Clinical Trials Launched Before and During the COVID-19 Pandemic. *JAMA Network Open*. 2021;4(1):e2036353. doi:10.1001/jamanetworkopen.2020.36353
273. Akenroye AT, Heyward J, Keet C, **Alexander GC**. Lower Use of Biologics for the Treatment of Asthma in Publicly-insured Individuals. *J Allergy Clin Immunol Pract*. 2021 Feb 5:S2213-2198(21)00169-0. doi: 10.1016/j.jaip.2021.01.039. Epub ahead of print. PMID: 33556592.
274. Garibaldi BT, Wang K, Robinson ML, et al. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. *JAMA Netw Open*. 2021;4(3):e213071. doi:10.1001/jamanetworkopen.2021.3071
275. Anderson KE, Saloner B, Eckstein J, Chaisson CE, Scholle SH, Niles L, Dy S, **Alexander GC**. Quality of Buprenorphine Care for Opioid Use Disorder. *Medical Care*. 2021;59:393-401.
276. Sen A, Kang SY, Rashidi E, Ganguli D, Anderson G, **Alexander GC**. Use of Copayment Offsets for Prescription Drugs in the United States. *JAMA Intern Med*. Published online March 29, 2021. doi:10.1001/jamainternmed.2021.0733
- Editorial: Yeung K, Dusetzina SB. Prescription Drug Out-of-Pocket Cost Reduction Programs: Incentives and Implications. *JAMA Intern Med*. Published online March 29, 2021. doi:10.1001/jamainternmed.2021.0739
277. Daubresse M, **Alexander GC**, Crews DC, Segev DL, Lentine K, McAdams-DeMarco MA. High-dose Opioid Utilization and Mortality Among Individuals Initiating Hemodialysis. *BMC Nephrol* 22, 65 (2021). <https://doi.org/10.1186/s12882-021-02266-5>
278. **Alexander GC**, Emersen S, Kesselheim AS. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility. *JAMA*. 2021 Mar 30. doi: 10.1001/jama.2021.3854. Epub ahead of print. PMID: 33783469.
279. Wang L, Paller CJ, Hong H, Rosman L, Felice AD, Brawley O, **Alexander GC**. Efficacy and safety of treatments for nonmetastatic castration-resistant prostate cancer: a matching adjusted indirect

comparison and network meta-analysis. *J Natl Cancer Inst.* 2021 Apr 8:djab071. doi: 10.1093/jnci/djab071. Epub ahead of print. PMID: 33830214.

280. Anderson KE, **Alexander GC**, Niles L, Scholle SH, Saloner B, Dy SM. Quality of Preventive and Chronic Care for Individuals with Opioid Use Disorder. *JAMA Open.* 2021;4:e214925.
281. Mehta HB, Wang L, Malagaris I, Duan Y, Rosman L, **Alexander GC**. More Than Two-dozen Prescription Drug-Based Risk Scores Are Available for Risk Adjustment: A Systematic Review. *J Clin Epidemiol.* 2021 Apr 7:S0895-4356(21)00111-6. doi: 10.1016/j.jclinepi.2021.03.029. Epub ahead of print. PMID: 33838274.
282. Derington CG, Cohen JB, Green TH, et al. Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use and COVID-19 severity and mortality among US Veterans. *PLoS ONE.* 2021;16:e0248080.
283. Zhang H, Wen J, **Alexander GC**, Curtis JR. Comparative Effectiveness of Interleukin- and Tumor Necrosis Factor (TNF)-Alpha Inhibitors for Psoriatic Arthritis. *RMD Open.* Publication pending.
284. Guadamuz JS, Wilder JR, Mouslim MC, Zenk S, **Alexander GC**, Qato DM. Fewer Pharmacies in Black and Hispanic/Latino Neighborhoods Compared With White or Diverse Neighborhoods, 2007-2015. *Health Aff (Millwood).* 2021 May;40(5):802-811. doi: 10.1377/hlthaff.2020.01699. PMID: 33939507.
285. Heyward J, Christopher J, Sarkar S, Shin JI, Kalyani RR, **Alexander GC**. Ambulatory Treatment of Type 2 Diabetes Mellitus in the United States, 2015-2019. *Diabetes Obes Metab.* 2021 Apr 21. doi: 10.1111/dom.14408. Epub ahead of print. PMID: 33881795.
286. Mehta HB, An H, Andersen KM, Mansour O, Madhira V, Rashidi ES, Bates B, Setoguchi S, Joseph C, Kocis PT, Moffitt R, Bennett TD, Chute CG, Garibaldi BT, **Alexander GC**; National COVID Cohort Collaborative (N3C). Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study. *Ann Intern Med.* 2021;174:1395-1403. doi: 10.7326/M21-0857. Epub 2021 Aug 17. PMID: 34399060; PMCID: PMC8372837.
- Editorial: Glesby MJ, Gulick RM. Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence. *Ann Intern Med.* 2021;174(10):1464-1465. doi:10.7326/M21-3221
287. Kahkoska AR, Abrahamsen TJ, **Alexander GC**, Bennett TD, Chute C, Haendel MA, Klein K, Mehta H, Miller J, Moffitt R, Stürmer T, Kvist K, Buse JB. Association Between Glucagon-like Peptide 1 Receptor Agonist and Sodium Glucose Co-transporter 2 Inhibitor Use and COVID-19 Outcomes: A National Retrospective Cohort Study. *Diabetes Care.* Publication pending.
288. Mehta HB, Kuo YF, Raji M, Westra J, Boyd C, **Alexander GC**, Goodwin JS. State Variation in Opioid Use in Long-term Care Nursing Home Residents. *Journal of the American Medical Directors Association.* Publication pending.
289. Foti K, Heyward J, Tajanlangit M, Meek K, Jones C, Kolodny A, **Alexander GC**. Primary Care Physicians' Preparedness to Treat Opioid Use Disorder in the United States: A Cross-sectional Survey. *Drug Alcohol Depend.* 2021 Aug 1;225:108811. doi: 10.1016/j.drugalcdep.2021.108811. Epub 2021 Jun 18. PMID: 34175786.

290. Andersen MS, Lorenz V, Pant A, Bray JW, **Alexander GC**. Effect of Prescription Opioid Utilization Management on Opioid Prescribing, Fatal and Non-Fatal Overdose Among U.S. Medicare Beneficiaries. *American Journal of Managed Care*. Publication pending.
291. Hwang YJ, **Alexander GC**, An H, Moore TJ, Mehta HB. Risk of Hospitalization and Death Associated with Pimavanserin Use in Older Adults with Parkinson's Disease: A Population-based Cohort Study. *Neurology*. 2021;97:e1266-e1275. doi: 10.1212/WNL.0000000000012601. Epub 2021 Aug 13.
292. **Alexander GC**, Karlawish J. The Problem of Aducanumab (Aduhelm) for the Treatment of Alzheimer Disease. *Annals of Internal Medicine*. 2021 Jun 17. doi: 10.7326/M21-2603. Epub ahead of print. PMID: 34138642.
293. Cortez C, Mansour O, Qato DM, Stafford RS, **Alexander GC**. Increased Telemedicine Use and Changes in Acute, Chronic and Preventive Care in the United States During the COVID-19 Pandemic. *JAMA Health Forum*. Publication pending.
294. **Alexander GC**, Knopman D, Emersen S, Ovbiagele B, Kryscio R, Perlmutter J, Kesselheim AS. Use of Beta-amyloid as Clinical Surrogate in Alzheimer's Disease: Revisiting U.S. Food and Drug Administration Approval of Aducanumab. *N Engl J Med*. 2021;385:769-771.
- Editorial: Rabinovici GD. Controversy and Progress in Alzheimer's Disease – FDA Approval of Aducanumab. *N Engl M Med*. 2021;385:769-771.
- FDA Response: Dunn B, Stein P, Temple R, Cavazzoni P. An Appropriate Use of Accelerated Approval – Aducanumab for Alzheimer's Disease. *N Engl M Med*. 2021;385:769-771.
295. Guadamuz JS, Wilder JR, Mouslim MC, Zenk S, **Alexander GC**, Qato DM. Access to Pharmacies and Pharmacy Services in New York City, Los Angeles, Chicago and Houston, 2015-2020. *Journal of the American Pharmacists Association*. Available at: <https://www.sciencedirect.com/science/article/abs/pii/S1544319121003101> (Accessed August 6, 2021).
296. Baksh S, Wen J, Mansour O, Chang HY, McAdams-DeMarco M, Segal JB, Ehrhardt S, **Alexander GC**. Dipeptidyl Peptidase-4 Inhibitor Use Cardiovascular Safety in Patients with Type 2 Diabetes, With Cardiovascular and Renal Disease: A Retrospective Cohort Study. *Sci Rep* 11, 16637 (2021). <https://doi.org/10.1038/s41598-021-95687-z>
297. Moore TJ, Wirtz P, Kruszewski SP, **Alexander GC**. Use of Prescription Stimulants Among Adults in the United States, 2013-2018. *BMJ Open*. 2021;11:e048528.
298. Kang SY, Sen A, Long J, **Alexander GC**, Anderson G. Factors Associated with Manufacturer Drug Coupon Use at U.S. Pharmacies. *JAMA Health Forum*. 2021;2:e212123.
299. Ballreich J, Bennett C, Moore TJ, **Alexander GC**. Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication. *JAMA Oncol*. Published online September 23, 2021. doi:10.1001/jamaoncol.2021.4757
300. Sarkar S, Heyward J, **Alexander GC**, Kalyani RR. Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020. *JAMA Netw Open*. 2021;4:e2128782. doi:10.1001/jamanetworkopen.2021.28782

301. Umarje S, **Alexander GC**, Cohen A. Ambulatory Fluoroquinolone Use in the United States, 2015 to 2019. *Open Forum Infectious Diseases*, 2021; <https://doi.org/10.1093/ofid/ofab538>
302. **Alexander GC**, Ballreich J, Mansour O, Dowdy DW. Effect of Reductions in Prescribing on Opioid Use Disorder and Fatal Overdose in the United States: A Dynamic Markov Model. *Addiction*. 2021 Sep 29. doi: 10.1111/add.15698. Epub ahead of print. PMID: 34590369.
303. Thrul J, Riehm KE, Cohen JE, **Alexander GC**, Vernick JS, Mojtabai R. Tobacco control policies and smoking cessation treatment utilization – a moderated mediation analysis. *PLoS One*. 2021 Aug 30;16(8):e0241512. doi: 10.1371/journal.pone.0241512. PMID: 34460821; PMCID: PMC8405013.
304. Padula W, Malaviya S, Reid NM, Tierce J, **Alexander GC**. Economic Value of Treatment and Vaccine to Address the COVID-19 Pandemic: A U.S. Cost-effectiveness and Budget Impact Analysis. *Journal of Medical Economics*. 2021;24:1060-1069. PMID: 34357843.
305. Andersen KM, Bates B, Rashidi ES, Olex A, Mannon RB, Patel RC, Singh J, Sun J, Auwaeter PG, Ng DK, Segal JB, Garibaldi BT, Mehta HB, **Alexander GC**, for the National COVID Cohort Collaborative (N3C) Consortium. Use of Chronic Immunosuppressive Medicines and In-hospital COVID-19 Outcomes: A Retrospective Cohort Study Using The National COVID Cohort Collaborative (N3C). *The Lancet Rheumatology*. November 15, 2021. DOI: [https://doi.org/10.1016/S2665-9913\(21\)00325-8](https://doi.org/10.1016/S2665-9913(21)00325-8)
- Editorial: Liew DFL, Robinson PC. What does endemic COVID-19 mean for the future of rituximab? *The Lancet Rheumatology*. November 15, 2021
306. Thakrar AP, **Alexander GC**, Saloner B. Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021. *JAMA Netw Open*. 2021;4(12):e2138807. doi:10.1001/jamanetworkopen.2021.38807
307. Garibaldi BT, Wang K, Robinson M, Betz J, Alexander GC, Andersen KM, Joseph C, Mehta HB, Korwek K, Sands K, Bollinger B, Xu Y, on behalf of the COVID-19 Consortium of HCA Healthcare and Academia for Research GENERation (CHARGE). Real-World Effectiveness Of Remdesivir In Adults Hospitalized With Covid-19: A Retrospective, Multicenter Comparative Effectiveness Study. *Clin Infect Dis*. 2021 Dec 15:ciab1035. doi: 10.1093/cid/ciab1035. Epub ahead of print. PMID: 34910128.
308. Wang L, Hong H, **Alexander GC**, Brawley O, Paller C, Ballreich J. Cost-effectiveness of Systematic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis. *Value in Health*. Published December 01, 2021. DOI:<https://doi.org/10.1016/j.jval.2021.10.016>
309. Anderson KE, **Alexander GC**, Ma C, Dy SM, Sen AP. Medicare Advantage Coverage Restrictions for Expensive Physician-Administered Drugs. *American Journal of Managed Care*. Publication pending.
310. Hussaini SM, Gupta A, Anderson KE, Ballreich JM, Nicholas LH, **Alexander GC**. Biosimilar Uptake in Medicare Part D, 2015-2019: Implications for Congressional Drug Pricing Legislation. *JAMA Open*. Publication pending.
311. DiStefano M, **Alexander GC**, Polsky D, Anderson GF. Public Opinion and Policy Options Regarding U.S. Food and Drug Administration Approval of Aducanumab: A Nationally Representative Survey. *Journal of the American Geriatrics Society*. Publication pending.

312. Ardeshirrouhanifard S, An H, Goyal RK, Raji M, Segal J, **Alexander GC**, Mehta HB. Use of Oral Anticoagulants Among Individuals with Cancer and Atrial Fibrillation in the United States, 2010-2016. *American Journal of Medicine. Pharmacotherapy*. Under review.
313. Anderson KE, **Alexander GC**, Dy SM, Sen AP. Formulary Design for Physician-administered Drugs in Medicare Advantage. Under review.
314. Lin DH, Murimi IB, Kan H, Tierce J, Wang X, Nab H, Desta B, Hammond E, **Alexander GC**. Health Care Utilization and Costs of Systemic Lupus Erythematosus (SLE) in the United States: A Systematic Review. Under review.
315. Bauchner H, **Alexander GC**. Rejection of Aducanumab (Aduhelm) by the Healthcare Community: Lessons Learned and the Path Ahead. Under review.
316. Andersen KM, Joseph CS, Betz JF, Bollinger RC, Gupta A, Jackson JW, LeMaistre CF, Robinson ML, Streiff BM, Fisher AM, Ng DK, Segal JB, Mehta HB, **Alexander GC**, Garibaldi BT, on behalf of the COVID-19 Consortium of HCA Healthcare and Academia for Research GENERation (CHARGE). High Intensity Versus Standard Prophylaxis Anticoagulation Among Adults Hospitalized With COVID-19: A Retrospective Cohort Study. *BMJ*. Under review.
317. Mehta HB, Andersen KM, Zeger S, Segal SB, **Alexander GC**. Research and Reporting Methods: Using Comorbidity Indices for Risk Adjustment in Observational Research. Under review.
318. Sun J, Patel RC, Zheng Q, Madhira V, Olex AL, Islam JY, French E, Chiang TPY, Akselrod H, Moffitt R, **Alexander GC**, Andersen KM, Vinson AJ, Brown TB, Chute CG, Crandall KA, Franceschini N, Mannon RB, Kirk GD. COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally-representative, Multicenter, Observational Cohort Study. Under review.
319. Wong PJ, Mosley S, Ng TMH, Shooshtari A, **Alexander GC**, Qato DM. Changes in Anticoagulant and Antiplatelet Drug Supply at U.S. Hospitals During the COVID-19 Pandemic. Under review.
320. McGinty EE, Bicket MC, Stuart EA, **Alexander GC**, Barry CL, McCourt AD, Rutkow L. Effects of state opioid prescribing laws on use of opioid and other pain treatments among commercially insured U.S. adults. *Annals of Internal Medicine*. Under review.
321. **Alexander GC**, Mix LA, Choudhury S, Taketa R, Tomori C, Mooghali M, Fan A, Mars S, Ciccarone D, Patton M, Apollonio DE, Schmidt L, Steinman M, Greene J, Ling PM, Seymour AK, Glanz S, Tasker K. The Opioid Industry Documents Archive: A Living Repository of U.S. Opioid Litigation Documents. *PLoS One*. Under review.
322. Adhikari R, Jha K, Dardari Z, Heyward J, **Alexander GC**, Blaha MJ. National Trends in Prescribing of SGLT2 Inhibitors and GLP-1 Receptor Agonists by Cardiologists and Other Specialists, 2015-2020. *Journal of the American Heart Association*. Under review.
323. Alashqar A, Ishiwata R, Moss C, Andersen K, Yanek L, Bicket M, **Alexander GC**, Borahay MA. Predictors of New Persistent Opioid Use After Benign Hysterectomy. Under review.

324. Hammond ER, Lin DH, Nab H, Murimi IB, Kan H, Onasanya O, Tierce JC, Wang X, Desta B, **Alexander GC**. Association between organ damage and health-related quality of life in systemic lupus erythematosus: a systematic review. *Clinical Rheumatology*. Under review.
325. Ozenberger K, **Alexander GC**, Shin JI, Whitsel E, Qato DM. Use of Prescription Medicines with Cardiovascular Adverse Effects Among Older Adults in the United States. *Circulation*. Under review.
326. McGinty EE, Stone EM, Bicket MC, **Alexander GC**, Barry CL, Rutkow L. Unintended Negative Consequences of State Opioid Prescribing Laws: A Qualitative Study. Under review.
327. Shin JI, Sang Y, Selvin E, Chang AR, **Alexander GC**, Cohen CM, Coresh J, Shalev V, Chodick G, Karasik A, Grams ME. Use of Glucose-Lowering Medications in Type 2 Diabetes: Comparison Between Two Health Systems in the United States and Israel. *Mayo Clinic Proceedings*. Under review.
328. Alamgir J, Chen X, Yajima M, Ergas R, **Alexander GC**, Mehta H, Pfaff E, Moffit R, Haendel M, Chute CG, Gersing K, Abid MR. Melatonin does not show any positive effect on COVID-19 infection or treatment. Under review.
329. Ballreich J, Fernandez E, Cohen BG, Mansour O, Dowdy DW, **Alexander GC**. Projected Effects of the COVID-19 Pandemic on Fatal Opioid Overdose in the United States: A Dynamic Markov Model. *International Journal of Drug Policy*. Under review.
330. Moore TJ, Alami A, Chang J, **Alexander GC**, Mattison DR. Safety and Effectiveness of N-Methyl-D-aspartate (NMDA) Antagonists for Depression: A Review. Under review.
331. Mehta HB, An H, Li S, Goodwin JS, **Alexander GC**, Segal JB. Validation of a Summary Elixhauser Comorbidity Score for Use with the International Classification of Diseases 10<sup>th</sup> Revision (ICD-10-CM). Under review.
332. Alinsky RH, Pritchett L, **Alexander GC**, Chang HY, Saloner B. Buprenorphine Receipt by Insurance Status among Adolescents and Young Adults During COVID-19. Under review.
333. Bramante CT, Johnson SG, Garcia V, Evans MD, Harper J, Wilkins K, Huling J, Mehta H, **Alexander GC**, Tronieri J, Hong S, Kahkoska A, Alamgir J, Koraisly F, Hartman K, Yang K, Abrahamsen T, Sturmer T, Buse J. Diabetes medications and Associations with Covid-19 Outcomes in the N3C Database: A National Retrospective Cohort Study. *PLoS One*. Under review.
334. Akenroye A, Lassiter G, Jackson J, Keet C, Segal J, **Alexander GC**, Hong H. Comparative Efficacy of Mepolizumab, Benralizumab and Dupilumab in Individuals with Eosinophilic Asthma: A Bayesian Network Meta-analysis. Under review.
335. Alamgir J, Abid MR, Garibaldi B, Munir N, Setoguchi S, Hong SS, Chen X, Kocis PT, Yajima M, **Alexander GC**, Mehta HB, Madhira V, Ergas R, O'Brien TR, Bozzette S. Lack of Association Between Convalescent Plasma Administration and Length of Stay: A Hospital Day Stratified Multi-Center Retrospective Cohort Study. *medRxiv* 2021.05.04.21256627  
doi: <https://doi.org/10.1101/2021.05.04.21256627>
336. Mehta HB, An H, Ardeshirrouhanifard S, Raji MA, **Alexander GC**, Segal JB. Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults with Cancer and Atrial Fibrillation. Under development.

337. Qato DM, Lev R, Ventricelli DJ, Watanabe J, **Alexander GC**, Clark KJ. Addressing Barriers in Accessing Buprenorphine at Retail Pharmacies in the United States. Under development.
338. Kravchenko O, Boyce RD, Gomez-Lumbreras A, Kocis PT, Zapata LV, Tan M, Leonard C, Mehta H, **Alexander GC**, Andersen K, Malone DC. Potential drug-drug interaction of oral anticoagulants and dexamethasone, a nested case control study in the National COVID Cohort Collaborative (N3C). Under development.
339. Bress A, et al. Association between pharmacy deserts, blood pressure control and cardiovascular events among individuals with hypertension. Under development.
340. Wong P, Mosley S, Ng T, **Alexander GC**, Qato DM. Changes in the Supply of Antithrombic Drugs During the COVID-19 Pandemic. Under development.
341. Mehta H, Wu A, **Alexander GC**. Hospital-level Variation in COVID-19 Treatment Among Adults In the United States: A Retrospective Cohort Study. Under development.
342. Kang SY, **Alexander GC**, Liu A, Anderson G. Timing of Manufacturer Drug Coupon Use for Prescription Drugs in the United States. Under development.
343. Hermosilla M, **Alexander GC**, Polsky D. Employment Disruption and Access to Care of Chronic Medical Conditions: Evidence from Statin Sales During the Covid-19 Pandemic. Under development.
344. Saloner B, Chang HY, **Alexander GC**, Stein BD. Discontinuation of Treatment for Opioid Use Disorder During the COVID-19 Pandemic: A Multilevel Framework. Under development.
345. Qato DM, **Alexander GC**, Ventricelli DJ, Watanabe J, Lev R, Clark KJ. Addressing Dispensing Barriers to Buprenorphine Access at Retail Pharmacies in the United States. Under development.

*Articles and Editorials not peer reviewed (names of trainees are underlined)*

1. **Alexander GC**. "On Remaining Human." *Becoming Doctors*. Student Doctors Press, La Grange Park, IL: pp 226-228, 1995 (essay).
2. **Alexander GC**, Weiss A, George S. "Virtual Medical School." *The New Physician*. Oct 1996: 16-17 (manuscript).
3. **Alexander GC**. Course Guide – Caring for Patients Near the End-of-Life. Case Western Reserve University - School of Medicine, 1997;1-88 (curriculum).
4. **Alexander GC**, Weiss A. Providing laptops to promote computer use: lessons learned. *Academic Medicine*. 1998;73:224-225 (letter to editor).
5. **Alexander GC**. Patient care and student education. *Virtual Mentor: Ethics Journal of the American Medical Association*. Available at: <http://www.ama-assn.org/ama/pub/category/7678.html> Accessed April 26, 2002 (invited commentary).
6. **Alexander GC**, Kwiatkowski C. Diagnosing and managing adverse drug events in hospitalized patients. *Topics in Drug Therapy (University of Chicago)*. 2003;45:1-8. (manuscript)

7. **Alexander GC**, Casalino LP, Metzler DO. Factors in studying patient-physician communication. JAMA. 2003;290:2544. (letter)
8. **Alexander GC**. Prescriptions of sleep. Canadian Family Physician. 2004;50:543-545. (essay)
9. **Alexander GC**. Unnecessary tests and ethics of quality of care. Virtual Mentor: Ethics Journal of the American Medical Association. Available at: <http://www.ama-assn.org/ama/pub/category/12470.html> Accessed June 2, 2004. (invited commentary)
10. Sayla M, **Alexander GC**. An annotated bibliography exploring prescription cost-sharing. Prepared for the national meeting of the Society of General Internal Medicine. June, 2005. (annotated bibliography)
11. **Alexander GC**. Issue brief: Many physicians engaged in addressing health disparities. Developed on behalf of the Commission to End Health Disparities, April 2005. (issue brief)
12. **Alexander GC**. Geographic barriers and access to care. Virtual Mentor: Ethics Journal of the American Medical Association. 2005;7. Available at: <http://www.ama-assn.org/ama/pub/category/15218.html> Accessed July 5, 2005. (invited commentary).
13. **Alexander GC**. A crash course? What happens when a patient's medical and economic best interests collide? Virtual Mentor: Ethics Journal of the American Medical Association. 2006;8:147-149. (invited commentary)
14. Smith PJ, **Alexander GC**, Siegler M. Should editorials in peer-reviewed journals be signed? Chest. 2006;129:1395-1396. (Invited editorial)
15. **Alexander GC**, Lantos JD. Bioterrorism, public service, and the duty to treat. Cambridge Quarterly. 2006;15:422-423. (Invited commentary)
16. Torke AM, **Alexander GC**. Can healers have private lives? Virtual Mentor: Ethics Journal of the American Medical Association. 2006;8:441-448. Available at: <http://www.ama-assn.org/ama/pub/category/16375.html> Accessed July 26, 2006. (Invited commentary)
17. **Alexander GC**, Lantos J. The nuances of self-disclosure. Response to: "Physician self-disclosure in primary care visits: enough about you, what about me?" Arch Intern Med. 2008;168:242-244. (Letter to editor)
18. Torke A, **Alexander GC**, Lantos J, Siegler M. Response to letter regarding "The doctor-surrogate relationship." Archives of Internal Medicine. 2008;168:241-242. (Letter to editor)
19. **Alexander GC**. Dilemmas for a reason. Journal of Clinical Ethics. 2008;19:70-71. (Invited commentary)
20. Lale A, **Alexander GC**. The Urban Health Initiative: a story of one academic medical center and the underserved. SGIM Forum. December 2008. (Invited editorial)
21. Torke AM, **Alexander GC**, Lantos J. Substituted judgment. Journal of General Internal Medicine. 2009;24:146. (Letter to editor, reply).

22. Saunders M, **Alexander GC**. Turning and churning: loss of health insurance among adults in Medicaid. *Journal of General Internal Medicine*. 2009;24:133-4. (Invited editorial)
23. Walton SM, Schumock GT, Lee KV, **Alexander GC**, Meltzer D, Stafford RS. Importance of distinguishing supported and unsupported off-label use. *Archives of Internal Medicine*. 2010;170:657-658. (Letter to editor, reply)
24. Qato DM, **Alexander GC**. Response to: Hartung DM, Evans D, Haxby DG, Kraemer DF, Andeen G, Fagnan LJ. Effect of Drug Sample Removal on Prescribing in a Family Practice Clinic *Ann Fam Med* 2010 8:402-409. (Letter to editor, reply)
25. **Alexander GC**. Clinical prescribing (and off-label use) in a second-best world. *Medical care*. 2010;48:285-287. (Invited editorial)
26. Health IQ:2011. The Frontiers of Healthcare Advancement. IMS Institute for Healthcare Informatics. Diffusion of Innovation: Patterns and Effects. (Invited Chapter).
27. **Alexander GC**. Researcher's Corner: Talk Early and Often. *SGIM Forum*. 2011;34:5.
28. Dusetzina S, **Alexander GC**. Drug vs. Class-Specific Black Box Warnings: Does One Bad Drug Spoil the Bunch? *Journal of General Internal Medicine*. 2011;26:570-572. (Invited editorial)
29. **Alexander GC**. Seeding trials and the subordination of science. *Arch Intern Med*. 2011;171:1107-1108. (Invited editorial)
30. deSouza JA, **Alexander GC**. Unsupported off-label use of cancer therapies: new challenges in the era of biopharmaceuticals. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2011;11:495-498. (Invited editorial)
31. Qato DM, **Alexander GC**. Just Because It's Low Cost Doesn't Mean It's Accessible. *Journal of General Internal Medicine*. 2012;27:1233-1234. (Invited editorial)
32. Tan J, **Alexander GC**, Segal JB. Academic Centers Play a Vital Role in the Study of Drug Safety and Effectiveness. *Clin Ther*. 2013;35:380-384. (Invited editorial)
33. **Alexander GC**. Curious Conundrums of Off-label Prescribing. *PM&R*. 2013;5:882-889. (Invited editorial)
34. Fain K, **Alexander GC**. Are FDA Prescription Drug Safety Plans Working: A Case Study of Isotretinoin. *Pharmacoepidemiology and Drug Safety*. Pending publication. (Invited editorial)
35. Fain K, **Alexander GC**. Are FDA Prescription Drug Safety Plans Working: A Case Study of Isotretinoin. *Pharmacoepidemiology and Drug Safety*. 2014;23:440-441. (Invited response to letter to the editor).
36. Fain K, **Alexander GC**. Drug Postmarketing Studies--Reply. *JAMA*. 2013;310:2459-2460. (Invited response to letter to the editor)
37. **Alexander GC**. Capsule Commentary on Faerber and Kreling, "Content Analysis of False and Misleading Claims in Television Advertising for Prescription and Nonprescription Drugs". *Journal of General Internal Medicine*. 2014;29:180. (Invited commentary)

38. Fain K, **Alexander GC**. Mind the Gap: Understanding the Effects of Pharmaceutical Direct-to-Consumer Advertising. *Medical Care*. 2014;52:291-293. (Invited editorial)
39. Hwang CS, **Alexander GC**. Commentary on “Tamblyn R, Egualé T, Huang A, Winslade N, Doran P. The incidence and determinants of primary nonadherence with prescribed medication in primary care: a cohort study. *Ann Intern Med*. 2014;160:441-50.” Failure to Fill a First Prescription of a New Medication is Common in Primary Care Settings. *BMJ Evidence Based Medicine*. 2014;19:196. (Invited commentary)
40. Fain K, **Alexander GC**. Disposing of Medicines Safely. *American Journal of Public Health*. 2014;104:e2-3. (Letter to the editor)
41. Daubresse M, Fain K, **Alexander GC**. The Conversation. Upscheduling Hydrocodone. Pending publication. (Invited commentary)
42. Riggs KR, **Alexander GC**. Cost Containment and Patient Well-Being. *Journal of General Internal Medicine*. 2015;30:701-702. (Invited editorial)
43. **Alexander GC**, Keyes E. The Best Medicine: A Good Relationship With Your Doc. *The Baltimore Sun*. May 7, 2015. (Op-Ed)
44. Lyapustina T, **Alexander GC**. The Prescription Opioid Epidemic: A Problem of Our Own Making. *The Pharmaceutical Journal*, 13 June 2015, Vol 294, No 7866, online | DOI: 10.1211/PJ.2015.20068579 (Invited editorial)
45. Iyer G, **Alexander GC**. Cardiovascular Outcomes Associated with Clarithromycin. *BMJ*. 2016;352:i23 (Invited editorial)
46. Dy S, Wegener S, **Alexander GC**, Suarez-Cuervo C, Bass E. Comparative Effectiveness of Alternative Strategies for Decreasing Initiation of Opioids for Managing Chronic Pain. *PCORI Topic Brief*. The Johns Hopkins Evidence Based Practice Center. February 2016.
47. Qato DM, Alexander GC. Fish Oils and Bleeding: Where Is the Evidence? – In Reply. *JAMA Internal Medicine*. 2016;176(9):1406-1407.
48. Barrett K, Lucas E, **Alexander GC**. How Polypharmacy Has Become a Medical Burden Worldwide. *The Pharmaceutical Journal*. June 9, 2016. Available at: <http://www.pharmaceutical-journal.com>
49. Murimi IB, **Alexander GC**. Opiate overdose as a patient safety problem [Perspective]. *AHRQ PSNet* [serial online]. May 2017. Available at: <https://psnet.ahrq.gov/perspectives/perspective/225>.
50. **Alexander GC**. In Ali AK, Hartzema AG (eds). *Post-Authorization Safety Studies of Medicinal Products: The PASS Book*. In press. (Forward)
51. Qato DM, **Alexander GC**, Lindau ST. AAP’s Section on Integrative Medicine Suggests a More Balanced Approach to Dietary Supplement Data – In Reply. *Pediatrics*. In press.
52. Herder MR, Doshi P, Wallach JD, et al. FDA to Begin Releasing Clinical Study Reports in Pilot Programme. *BMJ*. 2018;360:k294. (Letter to the editor)

53. Mudumbai S, Stafford RS, **Alexander GC**. Having Surgery? Beware of Risk from Post-Op Opioids. USA Today. February 12, 2019. (Op-Ed)
54. **Alexander GC**, Sharfstein J. Opioid epidemic: Fighting addiction and chronic pain together to save lives. USA Today. April 25, 2019. (Op-Ed)
55. **Alexander GC**, Kolodny A. In Reply: Initial Opioid Prescriptions Among U.S. Commercially Insured Patients, 2012-2017. New England Journal of Medicine. May 2019. (Letter to editor)
56. Heyward J, Sharfstein S, **Alexander GC**. Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program—Reply. JAMA Internal Medicine, 2020. (Invited response to letter to the editor)
57. **Alexander GC**, Kesselheim AS, Moore TJ. Searching for an Effective Covid-19 Treatment: Promise and Peril. STAT. April 10, 2020. (Op-Ed)
58. Rashidi E, Andersen KM, Akenroye A, Xu Y, **Alexander GC**, Mehta H. In Reply: In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19 – Reply. Cell Metabolism. September 2020. (Comment to Editorial Board)
59. Qato DM, **Alexander GC**, Lindau ST. Access to Pharmacist-Prescribed and Emergency Contraception in Los Angeles County, 2017—Reply. Health Affairs, 2020. (Invited response to letter to the editor)
60. Wang L, Paller CJ, Hong H, De Felice A, **Alexander GC**, Brawley O. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. – In Reply.
61. Alinsky R, **Alexander GC**. Opioid Use Disorder During Pregnancy: Long-term Developmental Outcomes. Dev Med Child Neurol. 2021 Sep;63(9):1016. doi: 10.1111/dmcn.14972. Epub 2021 Jun 28. PMID: 34181246. (Invited Commentary)
62. Grecius M, **Alexander GC**. This Alzheimer’s Drug Doesn’t Merit Government Approval. New York Times. May 2021. (Op-Ed)
63. Yang X, Sun J, Patel RC, Zhang J, Guo S, Zheng Q, Olex AL, Olatosi B, Weissman SB, Islam JY, Chute CG, Haendel M, Kirk GD, Li X, for the National COVID Cohort Collaborative (N3C) Consortium. Under development. (Consortium Author)
64. Hwang YJ, **Alexander GC**, An H, Moore TJ, Mehta HB. Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. Neurology. 2022 Jan 4;98(1):49-50. doi: 10.1212/WNL.0000000000013043. PMID: 34965990.

*Monographs, book chapters and other scientific reports*

1. **Alexander GC**, Wynia MK. Survey research in bioethics. In “Empiric Methods for Bioethics: A Primer.” Eds: Jacoby L, Siminoff LA. Elsevier Press, New York, New York, 2007”.
2. Quinn MT, Gnepp J, **Alexander GC**, Hollingsworth D, O’Connor KG, Lang W, Klayman J, Meltzer DO. Design and Evaluation of Worksite Promotions of Organ Donation: Real-world Challenges and

- Practical Solutions. In “Understanding organ donation: applied behavioral science perspectives.” Eds: Siegel JT, Alvaro EM. Blackwell/Claremont Applied Social Psychology Series. Wiley-Blackwell, Chichester, West Sussex, United Kingdom, 2010.
3. Saunders M, **Alexander GC**, Siegler M. Clinical ethics and the practice of hospital medicine. In “Principles and Practice of Hospital Medicine.” Eds: McKean, Ross, Dressler, Brotman, Ginsberg. McGraw-Hill Companies, 2012 (2<sup>nd</sup> Edition printed 2016).
  4. **Alexander GC**, Frattaroli S, Gielen AC, eds. The Prescription Opioid Epidemic: An Evidence-Based Approach. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland: 2015
  5. Citizen Petition to the Food and Drug Administration (Signatory). Requesting that the Commission to the FDA place a black box warning on pharmaceuticals in the opioid and benzodiazepine classes warning patients of the potential serious risks with concomitant use of both classes of medications. Submitted February 22, 2016. Petition granted August 31, 2016. Petition available at: [http://health.baltimorecity.gov/sites/default/files/Final%20Draft%20FDA%20petition-Full%20Co-Signers-2.19.16%20\(2\)%20\(1\).pdf](http://health.baltimorecity.gov/sites/default/files/Final%20Draft%20FDA%20petition-Full%20Co-Signers-2.19.16%20(2)%20(1).pdf) (Accessed September 1, 2016).
  6. Working Group Member. Transparency at the U.S. Food and Drug Administration: Recommendations to Support the Development of Safe and Effective Medical Products. October 2016.
  7. Working Group Member. Partnership Forum: Navigating Innovations in Diabetes Care. Journal of Managed Care and Specialty Pharmacy. December 2016.
  8. Sharfstein JM, Miller JD, Davis AL, Ross JS, McCarthy ME, Smith B, Chaudhry A, Alexander GC, Kesselheim AS. Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products. January 22, 2017.
  9. **Alexander GC**, Frattaroli S, Gielen AC, eds. The Opioid Epidemic: From Evidence to Impact. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland: 2017.
  10. Bicket MC, **Alexander GC**. Prescribing Guidelines and Opioid Stewardship. In “The Public Health Guide to Ending the Opioid Epidemic.” Prescribing Guidelines and Opioid Stewardship. In: A Public Health Guide to Ending the Opioid Epidemic. Edited by Michael R. Fraser PhD MS, Jay C. Butler MD and Philicia Tucker MPH, Oxford University Press (2019). DOI: 10.1093/oso/9780190056810.003.0023

#### *Other*

Designed and hosted a web site devoted to patient education and empowerment regarding prescription costs and polypharmacy. Previously available (2005-2012) at: <http://prescriptions.bsd.uchicago.edu/>

**CURRICULUM VITAE**  
G. Caleb Alexander, MD, MS

PART II

**TEACHING AND MENTORING (Johns Hopkins University, 2012-present)**

*Undergraduate students*

- Ian Day; Academic Advisor for Special Public Health Honors Thesis, 2020-2021

*Graduate students (iMPH or MPH Advisor)*

- Vibhuti Arya, PharmD; Academic Advisor for Part-time iMPH Program, 2012-2016
- Haley Gibbs, PharmD; Academic Advisor for Part-time iMPH Program, 2012-2015
- Ayu Katada; Academic Advisor for MPH Program (MPA/MBA Dual Degree), 2012-2014
- Etkar Argawal; Academic Advisor for MPH Program in Epidemiologic and Biostatistical Methods for Public Health and Clinical Research, 2013-2014
- Lee Meller, MD; Academic Advisor for Part-time iMPH Program, 2013-2014
- Sharonjit Sagoo, PharmD; Academic Advisor for Part-time iMPH Program, 2015-
- Carolyn Tieu, PharmD, Academic Advisor for MPH Program, 2016-2017
- Ken Ogasawara, PhD, Academic Advisor for MPH Program, 2016-2017
- Denise Lepley, Academic Advisor for Part-time iMPH Program, 2017-2018
- Juan Franco, MD, Academic Advisor for Part-time iMPH Program, 2018-2020
- Varsha Lalchandani, Academic Advisor for Part-time iMPH Program, 2018-
- Rachel McFadden, Academic Advisor, Bloomberg American Health Fellow, 2019-
- Michael Kennedy, Academic Advisor, Bloomberg American Health Fellow, 2020-
- Sindhura Karlapudi, MBBS, Academic Advisor for MPH Program, 2020-2021

*Graduate students (MHS Advisor)*

- Francine Chingcuanco; Academic Advisor for MHS Program in Cardiovascular Epidemiology, 2014-2016
- Geetha Ayer; Academic Advisor for ScD Program in Cardiovascular Epidemiology, 2014-2016
- Meijia Zhou; Academic Advisor for MHS Program in General Epidemiology and Methodology, 2012-2014
- Jeffrey Yu; Academic Advisor for MHS Program in Health Economics, 2017-2018
- Hanzhe Zhang; Academic Advisor for MHS Program in General Epidemiology and Methodology, 2017-2020

*Graduate students (Capstone or Thesis Advisor)*

- Ayu Katada; Academic Advisor for MPH Program (MPA/MBA Dual Degree), 2012-2014
- Jinhee Moon, MHS; Capstone Advisor for MPH Program, 2012-2013 (Outstanding Achievement Award)
- Steven Jones; Capstone Advisor for MPH Program, 2012-2013
- David Nartey; Capstone Advisor for MPH Program, 2012-2013
- Tatyana Lyapustina; Capstone Advisor for MPH Program (MD/MPH Dual Degree), 2014-2015
- James Goldberg; Capstone Advisor for iMPH Program, 2015-2016
- Zoya Fansler; Capstone Advisor for Part-time iMPH Program, 2015-2016
- Jeong Ah Cho; Capstone Advisor for MPH Program (MPH/MBA Dual Degree), 2016-2018

- Shengyuan (David) Luo; Thesis Co-Advisor for MHS Program, 2016-2018
- Yunwen Xu; Thesis Advisor for MHS Program, 2016-2018
- Omar Mansour; Thesis Advisor for MHS Program, 2016-2018
- Jeffrey Rollman; Capstone Advisor for MPH Program, 2017-2018
- Nune Makarova; Capstone Advisor for MPH Program, 2017-2018
- Nisha Parikh; Capstone Advisor for MPH Program, 2018-2019
- Xintong Li; Thesis Advisor for MHS Program, 2017-2019
- Juan Franco, MD, Capstone Advisor for Part-time iMPH Program, 2018-2019
- Paul O'Malley, Capstone Advisor for Part-time iMPH Program, 2019
- Stephen Sander, Capstone Advisor for Part-time iMPH Program, 2020
- Margarita Sotelo, Capstone Advisor for Part-time iMPH Program, 2021
- Paul O'Malley, Capstone co-Advisor for Part-time iMPH Program, 2021
- Jesuseun Owoniyi, Capstone Advisor for Part-time iMPH Program, 2021
- Cameron Carlock, Capstone Advisor for Part-time iMPH Program, 2021

*Graduate Students (Doctoral Advisor or Dissertation Committee Member)*

- Kevin Fain, Dissertation Committee Member (DrPH/Epidemiology), 2012-2015
- Jingwen Tan, Dissertation Committee Member (PhD/Clinical Epidemiology), 2012-2016
- Shilpa Viswanathan, Dissertation Committee Member (PhD/Clinical Epidemiology), 2012-2015
- Richard Scott Swain, Dissertation Committee Member (PhD/Clinical Epidemiology), 2013-2015
- Christopher Kaufman, Dissertation Committee Member (PhD/Mental Health), 2013-2015
- Christine Buttorff, Dissertation Committee Member (PhD/Health Policy and Management), 2012-2014
- Remington Nevin, Dissertation Committee Member (PhD/Mental Health), 2014-2017
- Mariana Socal, Dissertation Committee Member (PhD/Mental Health), 2014-2017
- Lisa Selker, Dissertation Committee Member (PhD/University of North Carolina Rollings School of Public Health), 2015-2020
- Sheriza Bakst, Doctoral Advisor (PhD/Epidemiology), 2015-2018
- Alex Secora, Doctoral Advisor (PhD/Epidemiology), 2016-2019
- Lucy Qiao, Doctoral Co-Advisor (PhD/Epidemiology), 2017-2021
- Kathleen Anderson, Doctoral Co-Advisor (PhD/Epidemiology), 2018-2021
- Jiajun Wen, Dissertation Committee Member (PhD/Epidemiology), 2018-2021
- Thomas Metkus, Dissertation Committee Member (PhD/Graduate Training Program in Clinical Investigation [GTPCI]), 2019-
- Lin Wang, Doctoral Co-Advisor (PhD/Epidemiology), 2019-2021
- Katherine Ozenberger, Dissertation Committee Member (PhD/University of Illinois School of Pharmacy), 2019-
- Bingkai Wang, Dissertation Committee Member (PhD/Biostatistics), 2020-2021
- Lisa Dwyer, Part-time/online DrPH Program, Academic Advisor, 2020-
- Jennifer Black, Part-time/online DrPH Program, Academic Advisor, 2020-
- Brendan Rabideau, Dissertation Committee Member (PhD/Health Policy & Management), 2019-
- Ahizechukwu C Eke, Dissertation Committee Member (PhD/GTPCI), 2019-2021
- Corey Joseph, Doctoral Co-Advisor (PhD/Epidemiology), 2020-
- Ester Meche, Doctoral Co-Advisor (PhD/Epidemiology), 2021-

*Other Trainees (Post-doctoral or Junior Faculty)*

- Kevin Riggs, MD; Mentor for research program examining generic utilization and effect of drug coupons on drug utilization and expenditures, 2013-2016
- Mark Bicket, MD; Mentor of career development award activities focused on utilization, safety and

effectiveness of prescription opioids in peri-operative setting, 2016-2018

- Lori Dean, PhD; Mentor for CFAR Faculty Development Award, 2021-2022

#### *Classroom Instruction*

- Designer and Instructor, Pharmacoepidemiology: Drug Utilization, 2014-present (340.684.01)
- Co-Instructor, Design of Epidemiologic Studies: Proposal Development & Critique, 2015-present (340.715.01)
- Lecturer, Epidemiology of Aging (340.616.01)
- Lecturer, Pharmacoepidemiology Methods (340.682.01)
- Small Group Facilitator: Clinical Epidemiology, Johns Hopkins School of Medicine, 2014-2016
- Graduate Summer Institute of Epidemiology and Biostatistics: Pharmacoepidemiology (340.617.11)
  - Lecturer, 2012-2016
  - Designer and Co-Instructor, 2017-present
  - Excellence in Teaching Distinction for Course
- Lecturer, Graduate Training Program in Clinical Investigation, Principles of Drug Development, 2017-present

#### *Other significant teaching*

- Participate in informal mentoring with dozens of students through works in progress, journal clubs and seminar series within the Departments of Epidemiology (School of Public Health) and the Division of General Internal Medicine (Johns Hopkins Medicine)
- Co-lead Special Seminar Series “Pharmaceutical Safety, Value and Innovation” sponsored by Center for Drug Safety and Effectiveness

## **TEACHING (University of Chicago, 2001-2012)**

#### *Undergraduate students*

Mounica Yanamandala, University of Chicago, Primary mentor (2009-2011)  
Regina Depietro, University of Chicago, Primary mentor (2009-2011)  
Mateusz Ciejka, University of Chicago, Primary mentor (2009-2010)  
Sarah Gallagher, University of Chicago, Primary mentor (2008-2009)  
Maliha Darugar, University of Chicago, Primary mentor (2003-2006)  
Nadiyah Mohajir, Harris School for Public Policy, Honors thesis advisor (2002-2003)  
Diane McFadden, University of Chicago, Primary mentor (2002-2003)

#### *Graduate students*

Frank Liu, Department of Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago, Thesis committee (2008-2010)  
Teri Arthur, PhD, MSW, Social Services Administration, Dissertation Committee (2004-2008)  
Carolanne Dai, PhD, Harris School of Public Policy, Dissertation Committee (2002-2007)  
Sachiko Kuwabara, BA, Masters of Arts, University of Chicago (2004-2006)  
Melissa Brown, BA, Masters of Arts, University of Chicago (2005-2006)

#### *Medical students*

Erica MacKenzie, BA, Research Mentor (2011)  
Daniel Kozman, BA, Research Mentor (2010)  
Jessica Pirella, BA, Research Mentor (2010)  
Andrew Cohen, BA, Research Mentor (2009)

Michelle Stacey, BA, Research Mentor (2009)  
Karen Draper, BA, Research Mentor (2008)  
Allison Lale, BA, Research Mentor (2008)  
Rob Guzy, MD, PhD, Residency Advisor (2007)  
Susanne Phongsak, BA, Research Mentor (2006)  
Cesar Guerrero, BA, Research Mentor (2006)  
Patrick Lang, BA, Research Mentor (2004)  
Charles Kaufmann, MD, PhD, Residency Advisor (2004-2005)  
Stephanie Takahashi, MD, Residency Advisor (2005-2006)

#### *Residents*

Victoria Wong, MD, Editorial fellow, Journal of General Internal Medicine (2009-)  
Femi Aboyeji, MD, Research elective mentor (2007)

#### *Fellows*

Jonas DeSouza, MD (2010-2012)  
David Brush, MD (2009-2012)  
Milda Saunders, MD, MPH (2008-2012)  
Health services research fellows. University of Chicago (2004-2012)  
MacLean Center for Clinical Medical Ethics, Lecturer (2003-2012)  
Rachel Caskey, MD, Primary mentor (2006-2008)  
Alexia Torke, MD, HRSA Fellow, Primary mentor (2005-2007)  
Tumaini Colker, MD, MBA, Robert Wood Johnson Clinical Scholar (2005-2006)  
Gretchen Schwarze, MD, MPH, Vascular Surgery (2003-2006)

#### *Post-doctoral fellows*

Dima Qato, PharmD, MPH, PhD (2011)  
Atonu Rabbani, PhD (2007-2009)

#### *Classroom Instruction*

Lecturer, The doctor-patient relationship in clinical practice (2002-2011)  
Lecturer, MacLean Center for Clinical Ethics Summer Intensive (2003-2011)  
Designer and lecturer, Research Design Course for RWJF Clinical Scholars (2004-2006)  
Designer and lecturer, Research Design Course for Fellow Summer Intensive (2004-2006)  
Lecturer, Introductory Course on the fundamentals of health services research

#### *Other significant teaching*

Group leader for medical student summer research program (2004-2011)  
National Youth and Leadership Forum, Faculty participant (2005-2010)  
Participant in 1:1 Mentoring Program, Society of General Internal Medicine, 2007

## **RESEARCH GRANT AND CONTRACT PARTICIPATION**

#### *Current support*

Charitable Grants: UCSF-JHU Opioid Industry Documents Archive

Purpose: To support a highly accessible, state-of-the-art digital archive of documents arising from opioid litigation for use by researchers, journalists, policymakers and other stakeholders

- New York State Office of the Attorney General (Insys Bankruptcy), \$250,000
- National Association of Attorneys General (McKinsey Settlement), \$1,000,000
- Bankruptcy Court of the District of Delaware (Mallinckrodt Bankruptcy), \$1,100,000

Grant: 1 T32 HL139426-01; 12/27/2017 – 12/26/2022; National Heart, Lung and Blood Institute (Alexander/Segal)

Purpose: To optimize the safe and effective use of medicines to treat heart, lung and blood diseases

Grant: 9/1/2014-8/31/2023; U.S. Food and Drug Administration Center of Excellence in Regulatory Science and Innovation (Alexander)

Purpose: To develop fundamental new knowledge and tools to advance regulatory science

Grant: R01DK115534-01A1; 8/01/18 07/31/22; National Institutes of Diabetes and Digestive and Kidney Diseases (Grams/Inker)

Purpose: To investigate the risk and benefits of specific medications across the range of kidney function within 5 large, global electronic health records

Grant: 1R01DA044987-01; 9/30/2017 – 7/31/2021; National Institutes of Drug Abuse (McGinty/Rutkow)

Purpose: To quantify the effect of state laws intended to curb high-risk opioid prescribing

Grant: 1 U01 FD005942-01; 9/1/2018-8/31/2022; Food and Drug Administration (Alexander)

Purpose: To enhance regulatory science through a unique FDA-academic partnership (CERSI)

Grant: 05/01/2019-02/28/2022; The Arnold Foundation (Andersen)

Purpose: To develop and enact legislation to lower drug prices and enhance access to pharmaceuticals

Grant: OT2HL161847-01; 10/1/21-05/23/22; National Heart, Lung and Blood Institute (Chute)

Purpose: To develop and enact a clinical science core, data resource core, and biorepository core for post-acute sequelae of SARS-CoV-2 infection

*Past support (selected list)*

Grant: 1R01DA042738-01; 02/01/17–11/30/20; National Institutes of Drug Abuse (Rutkow)

Purpose: To assess the association between clean indoor air laws, cigarette taxes, and use of smoking cessation treatments

Grant: 5 R21AG058132-02; 9/15/18 – 8/31/20; National Institute on Aging (Andersen)

Purpose: To quantify the effect of drug utilization management in the Medicare Part D program

Grant: 3/1/2019 – 2/29/2020; Cardinal Health (Qato)

Purpose: To conduct a pilot study exploring the potential role of telepharmacy in improving medication adherence in urban areas

Grant: 3R01DA044987-03S1; 8/1/2019 – 10/31/2019; National Institutes of Drug Abuse (McGinty/Rutkow)

Purpose: Landscape Review of U.S. Health Professional Pain Management Curricula

Grant: 8/1/17-4/30/19; The Arnold Foundation (Andersen)

Purpose: To evaluate and advance policies to achieve a “fair price” of high cost prescription drugs

Grant: 5/5/2017- 1/30/2018; Department of Health and Human Services/ASPE (Alexander)

Purpose: To describe the breadth and depth of coverage policies for acute and chronic back pain among a nationally representative selection of Medicaid, Medicare Advantage and commercial health plans

Grant: 7/1/2016-4/4/2017; AstraZeneca (Alexander)

Purpose: To quantify the disease burden and resource utilization associated with Systemic Lupus Erythematosus (SLE)

Grant: 12/2/2016-6/30/2017; AstraZeneca (Alexander)

Purpose: To characterize the association between organ damage, quality of life, and mortality among patients with Systemic Lupus Erythematosus (SLE)

Grant: ID# 72452; 2/15/2015-1/31/2017; Robert Wood Johnson Foundation (Rutkow)

Purpose: To understand role of interorganizational relationships, information sharing and legally established infrastructure on prescription drug monitoring programs' function and impact within the public health system

Grant # U01FD005556: 09/15/15-08/31/16; Food and Drug Administration (Varadhan)

Purpose: To develop structural nested models to assess safety and effectiveness of generic drugs

Grant: 1 R01 HL 107345-01; 4/1/11-3/31/15; NHLBI (Alexander, Co-PI)

Purpose: To examine the effect of DTCA on prescription and non-prescription health care utilization

Grant: 1 R01 AG034187-01; 7/1/2012-6/30/2015; National Institutes on Aging (Kaestner)

Purpose: To determine if Part D Prescription Coverage Improves Health and Reduces Inpatient Use

Grant: 1 U01 CE002499-01; 9/1/2014-9/1/2016; Center for Disease Control and Prevention (Alexander)

Purpose: To evaluate the effect of Florida's Pill-Mill Law on opioid prescribing, utilization and dispensing

Grant: ID# 24741; 7/1/2014-1/1/2016; Robert Wood Johnson Foundation (Alexander)

Purpose: To evaluate the effect of Prescription Drug Monitoring Programs on opioid prescribing, utilization and dispensing

Grant: 1 R01 HS 018960-01; 8/1/10-7/31/14; Agency for Health Care Quality and Research (Alexander)

Purpose: To assess the effect of FDA advisories on provider, patient, and firm behavior

Grant: 1 K08 HS15699-01A1; 2/01/06-2/01/11; Agency for Health Care Quality and Research (Alexander)

Purpose: To conduct a randomized trial to reduce patient's out-of-pocket prescription costs

Grant: Robert Wood Johnson Physician Faculty Scholars Award; 7/1/06-6/30/09; RWJ Foundation (Alexander)

Title: Development and evaluation of interventions to reduce patients' prescription costs

Contract: IMS Health Services Research Network; 10/1/10-12/31/11; IMS Health (Alexander)

Purpose: To develop and promote academic research network using IMS Health's data assets to address questions relevant to health care reform

Grant: UL1RR024999; 12/1/09-11/30/10; CTSA Institutional Pilot (Alexander)

Purpose: To quantify the impact of FDA advisories on psychotropic medication use among children

Grant: The University of Chicago Program for Pharmaceutical Policy; 2/01/05-6/1/09; The Merck Foundation (Meltzer)

Purpose: To foster innovative research at the University of Chicago in pharmaceutical policy with a focus on regulation, innovation, and technology assessment

Contract: HHS 290 200 500 381; 9/16/05-9/15/10; Agency for Health Care Quality and Research (Schumock)  
Title: Chicago Area Pharmaceutical Outcomes Research Consortium. Developing Evidence to Inform Decisions about Effectiveness: The DEcIDE Network

Grant: The Greenwall Foundation; 7/1/10-6/30/11 (Alexander)

Purpose: To conduct a mixed-methods study to examine management of conflict between physicians and surrogates of critically ill adults

Grant: Center for Education and Research on Therapeutics (CERT); 09/01/07 – 3/31/11; Agency for Health Care Quality and Research (Meltzer)

Purpose: To create an education and research infrastructure that produces and disseminates knowledge to improve the effectiveness and cost-effectiveness of the use of therapeutics

Grant: Mixed-methods exploration of the adoption of the HPV Vaccine; 10/1/07-9/30/08; University of Chicago Program for Pharmaceutical Policy Pilot Grant (Alexander)

Purpose: To establish prevalence and determinants of HPV vaccine uptake

Contract: HHS 290 200 500 381; 9/15/06-1/29/07; AHRQ (Walton)

Purpose: To develop a method of prioritization of research efforts on off-label drug use

Grant: R39OT03411-01-00; 10/01/04-09/30/07; Health Resources and Services Administration Division of Transplantation (Lang)

Purpose: To develop, implement, and assess workplace intervention to increase organ donor intention

Grant: The Medicaid Pharmacy Cost Containment and Patient Outcomes; 7/1/06-6/30/07; Center for Health and the Social Sciences - University of Chicago Pilot Grant (Alexander)

Purpose: To examine association between Medicaid cost-containment policies and clinical outcomes

Grant: Donald W. Reynolds Foundation; 9/1/03-8/31/07; National Institute of Aging (Sachs)

Purpose: Faculty Development in Geriatrics

Grant: Robert Wood Johnson Foundation Clinical Scholars Program; 7/1/03-7/1/06; Robert Wood Johnson Foundation (Lantos)

Purpose: To provide a post-residency academic program that trains scholars to apply pure research methods to health-related problems.

Grant: 1 H39 OT 00086-01; 10/01/01-09/30/04; Health Resources and Services Administration Division of Transplantation (Lang)

Purpose: To develop, implement, and assess a corporate workplace intervention designed to increase intention to become an organ donor

Grant: 5 K12 AG00488; 09/01/96-08/31/04; National Institute of Aging (Sachs)

Purpose: Geriatric Academic Program Award

## **ACADEMIC SERVICE**

2021-2024	Graduate Training Program in Clinical Investigation (GTPCI) Advisory Council
2021-2023	Faculty Senate, Johns Hopkins Bloomberg School of Public Health
2020-2023	Faculty Executive Committee (Member), Department of Epidemiology, JHSPH

2018-2021	Honors and Awards Committee (Chair), Department of Epidemiology, JHSPH
2016	Faculty Search Committee (John Jackson), Department of Epidemiology, JHSPH
2015	Faculty Search Committee (Mara McAdams), Department of Epidemiology, JHSPH
2015	Faculty Search Committee, Johns Hopkins Berman Institute of Bioethics
2014-2015	Graduate Training Program in Clinical Investigation (GTPCI) Review Committee
2014-2017	Admissions and Credentials Committee, Department of Epidemiology, JHSPH
2014-	Technology Transfer Committee, JHSPH
2013-2017	Curriculum Committee, Department of Epidemiology, JHSPH
2010-2012	Diabetes Research and Training Center, University of Chicago
2006-2010	Biological Sciences Division Institutional Review Board Member
2006	Steering Committee, Conference on Pharmaceutical Policy, Chicago, Illinois
2006-2008	Steering Committee, DOM Research Day, University of Chicago
2006-2008	Steering Committee, UOC Program in Pharmaceutical Policy, University of Chicago
2005-2006	Search Committee, UOC Comprehensive Cancer Center, Population Science Director
2003-2012	MacLean Center Ethics Committee, University of Chicago
2003-2008	Medicine and the Social Sciences, Co-Chair, University of Chicago
2000-2001	General Medicine Interest Group, Co-Chair, UPHS
2000-2001	Residency Review Committee, Class Officer, UPHS
1999-2001	Hospital of the University of Pennsylvania Ethics Committee, UPHS
1996-1997	Rainbow Babies and Children's Hospital Ethics Committee, CWRU
1994-1996	Class Officer and Chair, Committee of Student Representatives, CWRU

## INVITED SEMINARS OR ROUND TABLES

### *Local or Regional*

1. Racial differences in access and outcomes of kidney transplantation. Workshop on medicine and the social sciences. University of Chicago. November 2002.
2. Public support for physician deception of insurance companies. Council on ethical and judicial affairs, American Medical Association. Chicago, IL. April 2003.
3. Truth and lies: are the rules different for lawyers? Panel discussion at the American Bar Association Conference on Professional Responsibility. May 2003.
4. Patient-physician communication about out-of-pocket costs. Northwestern University, December 2002.
5. Patient-physician communication about out-of-pocket costs. Program in Medicine, Arts, and the Social Sciences. University of Chicago. Feb 2004.
6. Patient-physician communication about out-of-pocket costs. Program in Medicine, Arts, and the Social Sciences. University of Chicago. February 2004.
7. Is prescription choice rational? By whose standards? Pharmaceutical innovation and regulation: an American dilemma. Faculty workshop, University of Chicago. February 2004.
8. The doctor-patient relationship in the post-managed care era. American Medical Association. Chicago, IL. May 2004.

9. National trends in Cox-2 inhibitor use since market release: the non-selective diffusion of a selectively cost-effective innovation. Center for Pharmacoeconomics Research, University of Illinois School of Pharmacy. July 2004.
10. Division of Geriatrics Grand Rounds, University of Chicago Hospitals. A framework for medication prioritization and discontinuation. December 2004.
11. Department of Medicine Grand Rounds, University of Chicago Hospitals. Pharmaceutical innovation and the doctor-patient relationship: understanding the diffusion of Cox-2 inhibitors from 30,000 feet to the ground level. February 2005.
12. Bioethics Interest Group, Stritch School of Medicine, Loyola University. Physician deception of insurance companies. April 2005.
13. Midwest Center for Health Services and Policy Research. Hines Veterans Affairs System, Hines, IL. The diffusion of pharmaceutical innovation in the Veterans Affairs Health System. November 2005.
14. American Medical Student Association Panel Discussion. Pritzker School of Medicine, University of Chicago. Discussed role of industry in physician education and prescribing. November 2005.
15. Bioethics Interest Group. Pritzker School of Medicine, University of Chicago. Empiric ethics . . . or . . . what do numbers have to do with right and wrong? February 2006.
16. Chicago Medical Society. Panel discussion on medical ethics. Holiday Inn – Chicago Mart Plaza. Chicago, IL. March 2006.
17. Ethics dinner discussion with students from Pritzker Medical School, University of Chicago, May 2006.
18. The road less traveled – career paths in general internal medicine. National Youth Leadership Forum on Medicine, Chicago, IL. June 2006.
19. The Union League. Ethics considerations in pandemic planning. Chicago, IL. October 2006.
20. Attention: You have just entered the cost-sharing era: ethical, policy, and clinical considerations. Department of Medicine Research Series, December 2006.
21. Pharmacoths and pharmacothat: exploring topics in pharmaceutical research. University of Chicago Division of General Medicine Outcomes Group. March 2007.
22. Thinking globally, acting locally: a Chicagoland collaboration to unravel the impact of the Medicare Prescription Drug Benefit. TAP Pharmaceuticals. Chicago Midwest ISPOR Meeting. April 2007.
23. What do general internists do, and why? National Youth Leadership Forum on Medicine, Chicago, IL. June 2007.
24. The best of times, the worst of times: clinical decision-making and prescription choice in the 21<sup>st</sup> Century. Department of Otolaryngology. University of Chicago. October 2007.
25. What do we know about health care provider interaction with the pharmaceutical industry? University of Illinois Medical Center at Chicago Clinical Ethics Conference. March 2008.

26. Asking the right question(s) and getting funded to do so. University of Illinois at Chicago Advanced methods and grant writing workshop. March 2008.
27. Challenges and opportunities examining the off-label use of prescription medicines. Institute for Healthcare Studies. Northwestern University, Chicago, IL, May 2008.
28. Improving pharmacotherapy during outpatient care. Primary care medicine today (PRIMED) conference. Rosemont, IL, February 2009.
29. Choosing a research question: the perennial dilemma of “what shall I study”? Midwest Hospitalist Meeting. Chicago, IL. October 2009.
30. Conflicts of interest in medicine. Pritzker School of Medicine, University of Chicago. May 2010.
31. Using social network methods to study prescription drug uptake and diffusion. Department of Health Studies. University of Chicago. November 2010.
32. Managing risk through ethical practice. ISMIE Mutual Insurance Company. Chicago, IL 2010.
33. Overview of Clinical Epidemiology, in Fundamentals of Epidemiology. Johns Hopkins Krieger School of Arts and Sciences. November 2012.
34. The Prescription Opioid Epidemic: In Search of Mission Control.
  - Johns Hopkins Welch Center for Prevention, Epidemiology and Clinical Research Grand Rounds. December 2012.
  - University of Maryland Department of Pharmaceutical Health Services Research. April 2013.
  - Johns Hopkins Department of Medicine Osler Grand Rounds, October 2013.
  - Anne Arundel Medical Center Department of Medicine Grand Rounds, January 2014.
35. Drugs and Aging, in Epidemiology of Aging. Johns Hopkins Bloomberg School of Public Health. May 2013.
36. Career Development, in Public Health Economics Seminar. Johns Hopkins Bloomberg School of Public Health. September 2013.
37. The Effect of FDA Risk Communications on Patient, Provider and Firm Behavior. Johns Hopkins Department of Psychiatry Research Conference, December 2013.
38. Managing Prescription Opioids In Workers Compensation Programs. American Insurance Association. Washington, DC. June 2014.
39. Secondary Data Analysis. General Internal Medicine Fellows Conference. Johns Hopkins Medicine. Baltimore, MD. September 2014.
40. Center for Medical Technology Policy (CMTTP) Green Park Collaborative Annual Meeting. “Real World Evidence – Defining What “Good” Looks Like”. Panel Discussion. April 2015.
41. Safety, Efficacy and Pharmacokinetic Bioequivalence of Biosimilar TNF- $\alpha$  Inhibitors Compared with their Reference Biologics: A Systematic Review. Department of Clinical Pharmacology, Johns Hopkins Hospital. February 2016.

42. Reducing Prescription Drug Spending: A Review of Policy Options. Johns Hopkins Bloomberg School of Public Health. March 2016.
43. Keynote. Managing the Unmanageable: Reining in the Opioid Epidemic. CareFirst. Baltimore, Maryland, June 2017.
44. Moderator. Epidemiology Inclusion, Diversity, Equity & Science (Epi IDEAS) Communication with Policy Makers: The Opioid Epidemic. Panel Discussion featuring Lauren Jee and Amanda Latimore. Johns Hopkins Bloomberg School of Public Health. Baltimore, Maryland, January 2019.
45. Round Table Participant. National Center for Health Statistics. Data Dissemination of New Data: Alignment of Infrastructure Improvements on Opioid Use and Overdose with Researchers' Needs and Interests. Rockville, Maryland, July 2019.
46. Johns Hopkins Department of Pathology Symposium. The Opioid Epidemic. Baltimore, Maryland, September 2019.
47. Johns Hopkins Department of Epidemiology. Pivotal Trials for FDA-Approved Novel Therapeutic Agents: How Good is the Science, and What Does It Cost? Baltimore, Maryland, September 2019.

*National or International*

48. Panel discussion of interdisciplinary health professions education. Ohio League of Nursing Annual Meeting, Cleveland, Ohio, October 1996.
49. Grand Rounds, Department of Medicine, University of Pennsylvania: Pharmaceutical industry sponsorship of continuing medical education: training physicians or marketing products? June 2001.
50. Patient-physician communication about out-of-pocket costs. University of Michigan, January 2003.
51. Patient-physician communication about out-of-pocket costs. MetroHealth Medical Center, January 2003.
52. "Luxury care", professional standards, and personal choice: ethical and professional issues in retainer medical practices. Panel discussion at the American Society of Bioethics and Humanities Annual Meeting. October 2004.
53. Ad hoc pharmacoeconomics working group. AstraZeneca LP. Patient-physician communication about out-of-pocket costs. June 2005.
54. How much should \$38 billion buy? The uptake and impact of the Medicare Part D Prescription Benefit. Department of Medicine. VA Center for Health Equity Promotion and Research and University of Pittsburgh Department of Medicine. December 2007.
55. The Medicare Modernization Act Prescription Drug Benefit. Department of Ambulatory Care and Prevention, Harvard Medical School. January 2008.
56. Principles of survey research. Patan Academy of Health Sciences. Kathmandu, Nepal, April 2008.

57. Health care publishing in the peer-reviewed literature. Patan Academy of Health Sciences. Kathmandu, Nepal, April 2008.
58. Impact of FDA regulatory advisories on patient, provider and firm behavior. Mayo Clinic, April 2010; Virginia Commonwealth University, October 2010; Yale University, November 2010; Johns Hopkins University School of Medicine, November 2010; Johns Hopkins University School of Public Health, June 2011.
59. Special Guest: FED UP: Rally for a Federal Response to the Opioid Epidemic, National Sylvan Theater Stage at the Washington Monument, Washington DC, September 2014.
60. Panelist: Art and Science of Scientific Communications. CBI Advanstar. Publication Planning Forum. Philadelphia, PA. December 2014.
61. CMS Grand Rounds: The Opioid Epidemic. CMS Headquarters, Baltimore, MD. November 2015.
62. Panelist: Drug Safety and Surveillance. FDA/CMS Summit. IIR/IBC Life Sciences. Ritz Carlton Hotel, Washington DC, December 2015.
63. Special Guest: The Opioid Epidemic. American Insurance Association: Workers' Compensation Committee. Washington DC, February 2015.
64. Safety, Efficacy and Pharmacokinetic Bioequivalence of Biosimilar Tumor Necrosis Factor-alpha Inhibitors Compared with their Reference Biologics: A Systematic Review. Harvard Pilgrim Health Care. March 2016.
65. The Opioid Epidemic. Johns Hopkins Department of Pharmacy Grand Rounds. May 2016.
66. Guest Speaker: Innovations in Diabetes Care. Academy of Managed Care Pharmacy. Alexandria, Virginia, July 2016.
67. Panelist: Needed Changes in Federal Policy and Legislation to Address Nation's Opioid Crisis. Educational Briefing for Congressional Members and Staff. Washington, DC, September 2016.
68. Panelist: Balancing Opioid Access and Use. Academy of Managed Care Pharmacy Annual Research Symposium. Alexandria, Virginia, October 2016.
69. Keynote. An Evidence-Based Approach to the Opioid Epidemic. National Academy for State Health Policy. Pittsburgh, Pennsylvania, October 2016.
70. Special Guest Speaker. Science, Public Health and the Prescription Opioid Industry. Motley Rice LLC. Washington, DC, June 2017.
71. Guest Speaker. Opioid Prescribing Practices. Bloomberg Philanthropies. January 2018.
72. Plenary Speaker. Conundrums in Biotechnology: How Does Quality Impact Safety. World Congress of Biopharmaceuticals. Washington, DC, February 2018.
73. Special Invited Speaker. "Covering the Opioid Crisis". National Press Foundation. Washington, DC, February 2018.

74. Guest Panelist. “Addressing Prescription Drug Costs”. Johns Hopkins Carey School of Business Drug Accessibility and Pricing Symposium. Baltimore, MD, March 2018.
75. Guest Panelist. “Best Practices in Opioid Prescription, Pain Management, Medicine-Assisted Treatment and Recovery: New Models of Care for Opioid Use Disorder”. Modern Healthcare Opioid Symposium. Baltimore, MD, April 2018.
76. Invited Speaker. “Comparative Safety of NSAIDs and Opioids Among Hospitalized Patients: A Case Study”. Premier Annual Breakthroughs Conference. Nashville, TN, June 2018.
77. Guest Speaker. National Governor’s Association. Opioid Coverage Policy Roundtable. Washington, DC, June 2018.
78. Invited Panelist. National Black Caucus Foundation. Protecting the Health, Safety and Security of African American Communities. Health and Wellness Luncheon. Washington, DC, September 2018.
79. Session Moderator. State Legislative Leaders Foundation (SLLF) Fall Issues Summit. Addressing the Opioid Crisis. Baltimore, MD, September 2018.
80. Panelist. “Addiction Research – What is New and What is Interesting?” and “Why Recovery Research Matters and Why Residents and Alumni Should Participate”. Oxford House World Convention. Kansas City, MO, October 2018.
81. Facilitator. Academy of Managed Care Pharmacy Partnership Forum: “Building the Foundation for Patient-Reported Outcomes: Infrastructure and Methodologies”. Orlando, FL, November 2018.
82. Invited Panelist. National Academies of Science, Engineering and Medicine. “The Role of Nonpharmacological Approaches to Pain Management.” Washington, DC, December 2018.
83. Medicine Grand Rounds. Weill Cornell Medicine. “The Opioid Epidemic: Grief and Hope in the New Year”. New York, NY, January 2019.
84. Invited Panelist. OpioidX: New Approaches to Addressing the Opioid Crisis. MIT Sloan School of Management. Laboratory for Financial Engineering. Boston, MA, November 2020.
85. Invited Panelist. Electronic Prescribing of Controlled Substances (EPCS). American Medical Informatics Association. November 2020.
86. Invited Instructor. Academy of Managed Care Pharmacy (AMCP) Annual Meeting. Evidence behind COVID-19 Treatments and Vaccines. March 2021.
87. Co-developer. Bridging Faith and Science to Combat the Overdose Crisis. Partnership with Clinton Foundation, Johns Hopkins Bloomberg School of Public Health, and Centre for Responsible Leadership. Live Virtual Event featuring President Bill Clinton, Dr. Sanjay Gupta, Ellen J. MacKenzi, Bishop Vashti McKenzie, Dr. David Satcher and His Excellency Mohammad bin Abdulkarim Al-Issa. May 2021.
88. Invited Discussant. National Center for Health Research Panel on the COVID-19 Pandemic. “What Keeps Me Awake At Night and Other Things I Would Like To Know”. National Center for Health Research. May 2021.

89. Guest Speaker. “It Was the Best of Times, It Was the Worst of Times: The Curious Case of Aducanumab for the Treatment of Alzheimer’s Disease”.
- Bloomberg School of Public Health Department of Epidemiology. June 2021.
  - Bayview Medical Center Department of Medicine Grand Rounds. September 2021.
90. Panelist. FDA approves \$56,000 treatment for Alzheimer’s with Questionable Efficacy – What Happens Next? Johns Hopkins Business of Health Initiative. Johns Hopkins University. July 2021.
91. Invited Lecturer. The Aging and Memory Clinic Speakers Series at Saint Louis University. Aducanumab: Breaking Down the New Drug for Alzheimer’s Disease. September 2021.

## **NARRATIVE**

G. Caleb Alexander, MD, MS is a Professor of Epidemiology and Medicine at Johns Hopkins Bloomberg School of Public Health, where he serves as a founding co-Director of the Center for Drug Safety and Effectiveness and Principal Investigator of the Johns Hopkins Center of Excellence in Regulatory Science and Innovation (CERSI). He is a practicing general internist and pharmacoepidemiologist and is internationally recognized for his research examining prescription drug utilization, safety and effectiveness. Dr. Alexander is the author of over 350 scientific articles and book chapters, many using primary or secondary data to characterize the epidemiology of prescription opioid use in the United States as well as to evaluate the effect of federal and state regulatory and payment policies on opioid prescribing, dispensing and utilization. He has extensive experience disseminating these findings to both professional and lay audiences and has testified in front of both the U.S. House of Representatives and the U.S. Senate regarding his team's work. He is also one of three editors of a widely cited monograph produced by the Johns Hopkins Bloomberg School of Public Health that has provided comprehensive and concrete, evidence-based recommendations for addressing the opioid epidemic. Dr. Alexander received his B.A. cum laude from the University of Pennsylvania, an MD from Case Western Reserve University, and a Master of Science from the University of Chicago.

## **KEYWORDS**

Pharmacoepidemiology, pharmaceutical policy, regulation, internal medicine, opioids, opioid use disorder